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ABSTRACT
Methadone is a synthetic, long-acting opioid prescribed as an analgesic for chronic pain. It has a
single chiral center forming two enantiomers, (R)-methadone and (S)-methadone, each having
specific pharmacological actions. Concentrations of (R)- and (S)-methadone above therapeutic
levels have the ability to cause serious, life-threatening, and fatal side effects. Cardiotoxicity is
caused by elevated (S)-methadone levels by prolonging the QT interval of the heart’s electrical
cycle. In 2014, methadone accounted for only 1% of all opioids prescribed for pain, but was
responsible for 3,400 of the 14,838 individuals (~23%) who died in the United States from
overdoses due to prescription opioids. West Virginia (WV) and Kentucky (KY) continue to have
significant increases in overdose death rates involving prescription opioids. These overdoses
could be due in part to the pharmacogenetics of an individual, encompassing the ability to
influence the pharmacokinetic and pharmacodynamic properties of methadone, contributing to
toxicity. The principle determinant of the large interindividual variability of methadone
pharmacokinetics is metabolism, causing a discordance in the relationship between dose, plasma
concentrations, and side effects. Single nucleotide polymorphisms (SNPs) within the genes of
drug metabolizing enzymes, cytochrome P450 (CYP), may be important contributing factors in
altering CYP activity, methadone metabolism and pharmacodynamics. (S)-Methadone is
stereoselectively metabolized in the liver by CYP2B6. The purpose of this study was to
determine if one or more SNPs located within the CYP2B6 gene contributes to a poor
metabolizer phenotype for unexpected methadone deaths. A study cohort was obtained from the
WV and KY Offices of the Chief Medical Examiner consisting of 125 Caucasians who suffered
methadone-only fatal overdoses. Genotypic frequency of three intronic SNPs (rs2279344,
rs4803419, and rs8192719) and five exonic SNPs (rs3211371, rs3745274, rs8192709,
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rs12721655, and rs35979566) were investigated. The differences between the observed
genotypic frequencies were compared to the regional control group of 255 deceased Caucasian
individuals. The frequencies of the exonic SNP rs3745274 and intronic SNP rs8192719 were
enhanced in the methadone-only group. Higher blood methadone concentrations were observed
in individuals who were genotyped homozygous for SNP rs3211371. The five exonic SNPs
genotyped, and two others (rs2279343 and rs35773040), were individually expressed in COS-1
cells. The effect of these SNPs on the catalytic activity of the CYP2B6 enzyme was assessed by
evaluating the luminescence generated from the metabolism of luminogenic luciferin-2B6
substrate. Additionally, inhibition studies were also conducted using clopidogrel to determine
that the activity observed was from the CYP2B6 enzyme. Methadone was used to evaluate
competitive inhibition with luciferin-2B6 substrate at the active site. The effect on CYP2B6
activity by introducing individual SNP variants resulted in the following decreasing order:
rs2279343 > rs3745274 > wild type (CYP2B6*1), rs3211371 > rs8192709 > rs35773040,
rs35979566. Relative to the wild type CYP2B6, SNPs rs8192709, rs35773040, and rs35979566
yielded 57%, 81%, and 94% decreased activity, respectively. Methadone inhibited the activity of
the CYP2B6 enzyme by displacing the luciferin-2B6 substrate. Therefore, our investigations
suggest that the differences in catalytic activity by CYP2B6 allelic variants rs8192709,
rs35773040, and rs35979566 result in poor metabolizing phenotypes which may be contributing
factors in decreased metabolism of (S)-methadone. Because CYP2B6 only plays a partial role in
the metabolism of (S)-methadone, additional knowledge on the combination of SNPs on
CYP2B6, together with SNPs on other methadone metabolizing CYP genes, can improve the
proper therapeutic dosing for methadone, patient outcome, and the development of
individualized medicine.
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CHAPTER 1
EFFECTS OF CYTOCHROME P450 SINGLE NUCLEOTIDE POLYMORPHISMS ON
METHADONE METABOLISM AND PHARMACODYNAMICS
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Abstract
Methadone is a synthetic, long-acting opioid with a single chiral center forming two
enantiomers, (R)-methadone and (S)-methadone, each having specific pharmacological actions.
Concentrations of (R)- and (S)-methadone above therapeutic levels have the ability to cause
serious, life-threatening, and fatal side effects. This toxicity can be due in part to the
pharmacogenetics of an individual, which influences the pharmacokinetic and pharmacodynamic
properties of the drug. Methadone is primarily metabolized in the liver by cytochrome P450
(CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser
extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2. SNPs located within CYPs have the potential
to play an important role in altering methadone metabolism and pharmacodynamics. Several
SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma
concentrations, decreased N-demethylation, and decreased methadone clearance. In particular,
carriers of CYP2B6*6/*6 may have a greater risk for detrimental adverse effects, as methadone
metabolism and clearance are diminished in these individuals. CYP2B6*4, on the other hand, has
been observed to decrease plasma concentrations of methadone due to increased methadone
clearance. The involvement, contribution, and understanding the role of SNPs in CYP2B6, and
other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in
patient outcome and the development of personalized medicine.
1.1 Methadone Pharmacology
Shortly after methadone was introduced in the United States, the Food and Drug
Administration (FDA) approved its use as an analgesic and antitussive agent (Institute of
Medicine, 1995). During the 1960s, evidence for the usefulness of methadone in the treatment of
and maintenance therapy for narcotic addiction was growing (Dole & Nyswander, 1965; Joseph,
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Stancliff, & Langrod, 2000). A decade later, the FDA expanded the approval for physicians and
hospital pharmacies to dispense methadone for treating opiate addiction in treatment programs
only (Institute of Medicine, 1995). Enrollment in a methadone maintenance treatment (MMT)
program also has the potential to be a public health strategy for decreasing the transmission of
infectious diseases (e.g. HIV/AIDS, hepatitis C, or other blood-borne pathogens) by reducing the
number of opioid users reusing contaminated needles (Drucker, Lurie, Wodakt, & Alcabes,
1998; Joseph et al., 2000; Somogyi, Barratt, Ali, & Coller, 2014).
Methadone is a synthetic, long-acting opioid with a single chiral center that forms two
enantiomers, R-(-)-methadone (levo-methadone) and S-(+)-methadone (dextro-methadone)
(Anderson & Kearney, 2000; Lisberg & Scheinmann, 2013). Both enantiomers have specific
pharmacodynamic properties and pharmacological actions. (R)-Methadone is a µ-opioid receptor
(MOR) agonist that mimics the body’s natural endogenous opioids, endorphins and enkephalins.
Binding of (R)-methadone to the MOR mediates therapeutic effects with the release of other
neurotransmitters, including acetylcholine, dopamine, norepinephrine, and substance P
(Anderson & Kearney, 2000). The effects propagated by this interaction yields reduction and
elimination of drug cravings and withdrawal signs and symptoms of narcotics, analgesia,
sedation, nausea, vomiting, constipation, miosis, antitussive effects, hypotension, mild
bradycardia, and tolerance and dependence (Langrod, Lowinson, & Ruiz, 1981; Reisine, Law,
Blake, & Tallent, 1996; Li, Kantelip, Gerritsen-van Schieveen, & Davani, 2008; Mallinckrodt
Pharmaceuticals, Inc., 2016).
In the United States, methadone is clinically available only as a racemic formulation
comprised of both (R)- and (S)-methadone enantiomers (Gaertner, Voltz, & Ostgathe, 2008;
Kapur, Hutson, Chibber, Luk, & Selby, 2011; McCance-Katz, 2011). Methadone is currently
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used as: (1) an approved opioid substitution therapeutic agent to suppress opioid-abstinence
syndrome in opiate abuse and addiction (Stotts, Dodrill, & Kosten, 2009; Bart, 2012; Kreek et
al., 2012; Peles, Linzy, Kreek, & Adelson, 2013; McDonough, 2013); (2) a second-line opioid in
alleviating cancer pain and chronic non-malignant pain, such as back, joint, or neuropathic pain
and other forms of severe pain (Taylor et al., 2000; Toombs & Kral, 2005; Jackman, Purvis, &
Mallett, 2008; Fredheim, Moksnes, Borchgrevink, Kaasa, & Dale, 2009); and (3) a first-line
treatment in patients with both opioid dependence and chronic pain (Kahan, Srivastava, Wilson,
Mailis-Gagnon, & Midmer, 2006).
Methadone has contributed to a significant portion of opioid-related overdose deaths.
However, this outcome is not attributed to the use of methadone for opioid dependence, rather
from prescriptions of methadone for pain management (Jones, Baldwin, Manocchio, White, &
Mack, 2016). Reports from the Centers for Disease Control and Prevention (CDC) indicate a
15.6% increase in opioid death rates from 2014 to 2015. Conversely, methadone death rates
decreased by 9.1% due to factors such as efforts to reduce methadone therapy for pain, warning
labels, clinical guidelines, and limiting high dose formulations (Rudd, Seth, David, & Scholl,
2016). However, death rates continued to increase through 2014 resulting from methadone
overdosing in individuals between the ages of 55 – 64 years (Jones et al., 2016).
Concentrations of (R)- and (S)-methadone above therapeutic levels have negative and
detrimental side effects. Elevated (R)-methadone levels may depress ventilation, inducing
respiratory depression, by acting on the MORs expressed on respiratory centers in the brainstem
(Mitchell et al., 2004; Silverman, Nettleton, Spencer, Wallisch, & Olsen, 2009; van der Schier,
Roozekrans, van Velzen, Dahan, & Niesters, 2014). Conversely, an increase in (S)-methadone
disposition causes cardiotoxicity through the blockage of the voltage-gated potassium channel of
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the human ether-a-go-go related gene (hERG), subsequently prolonging the QT interval of an
electrocardiogram leading to torsades de pointes. (S)-Methadone is 3.5 times more potent than
(R)-methadone in blocking the hERG channel, thus attributing the stereoselectivity of methadone
to cardiotoxicity (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et al., 2013; Csajka, Crettol,
Guidi, & Eap, 2016).
Methadone is primarily eliminated via hepatic metabolism by cytochrome P450 (CYP)
enzymes through oxidative biotransformation. Methadone undergoes stereoselective Ndemethylation followed by spontaneous cyclization to form the principle, inactive metabolite 2ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (Figure 1) (Moody, Alburges, Parker,
Collins, & Strong, 1997; Oda & Kharasch, 2001; Ferrari, Coccia, Bertolini, & Sternieri, 2004;
Nanovskaya et al., 2004; Lehotay et al., 2005; Lugo, Satterfield, & Kern, 2005). Methadone has
a broad half-life of elimination ranging from 5 – 130 hours, with an average of 22 hours (Eap,
Buclin, & Baumann, 2002). This extreme inconsistency in the elimination half-life exemplifies
the large variability methadone possesses in its pharmacokinetics between individuals. Because
of the interindividual variation, it is difficult to predict an individual’s peak plasma levels, which
may result in some individuals having a higher than normal plasma level that approaches the
toxic or even fatal drug concentration. Comedication, age, gender, health, weight, and ethnicities
can all be factors that contribute to this effect.
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Figure 1: Eleven Methadone Metabolites Found in Human Excretion.
*
Indicates chiral carbon atom. ADH, alcohol dehydrogenase; CYP, cytochrome P450; EDDP, 2-ethyl-1,5-dimethyl-3,3diphenylpyrrolidine; EMDP, 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline; p-HO, para-hydroxy.
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Genetic variation occurs within and among populations, leading to polymorphisms. SNPs
are the most common type of genetic variation. A SNP is a variation of a single nucleotide at a
specific position in the genome, some of which may contribute to changes in a gene, either in the
coding (exons) or non-coding (introns) regions, or the regions between genes. A genetic
variation within CYP genes responsible for the metabolism of methadone may be causal for
altered function, which may result in methadone being rapidly eliminated from the body, thus
preventing the drug from reaching therapeutic levels. Alternatively, the genetic variation may
prolong elimination from the body, consequently, intensifying analgesic and detrimental adverse
effects (Daly, 2004; Smith, 2009). The purpose of this review is to focus on the effects of SNPs
of the various CYPs that metabolize methadone.
1.2 Methadone Metabolism
Eleven metabolites from methadone metabolism have been isolated and identified in
urine and feces in humans (Dinis-Oliveira, 2016). Methadone predominantly forms the
pharmacologically inactive pyrrolidine metabolites EDDP and 2-ethyl-5-methyl-3,3-diphenyl-1pyrroline (EMDP). Methadol and normethadol are active analgesic metabolites of methadone,
although this pathway is relatively minor (Sullivan & Due, 1973; Anggård et al., 1975). To a
lesser extent, methadone, normethadol, EDDP, and EMDP are further hydrolyzed to form
inactive p-hydroxy metabolites. Another minor pathway yields the inactive metabolites 4dimethylamino-2,2-diphenylvaleric acid, 4-methylamino-2,2- diphenylvaleric acid, and 1,5dimethyl-3,3-diphenyl-2-pyrrolidone (Figure 1) (Sullivan & Due, 1973; Anggård et al., 1975;
Dinis-Oliveira, 2016).
The CYP enzymes involved in the formation of methadone metabolites in humans are
CYP2B6, 3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2
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(Chang, Fang, Lin, & Moody, 2011). These CYPs, however, metabolize methadone in a
stereoselective manner, where CYP2C19, 3A7, and 2C8 preferentially metabolize (R)methadone, CYP2B6, 2D6, and 2C18 primarily metabolize (S)-methadone, and CYP3A4
demonstrates no stereoselectivity in methadone metabolism (Chang et al., 2011; Lemke,
Williams, Roche, & Zito, 2012). Methadone is N-demethylated to an intermediate compound,
normethadone, which is then spontaneously cyclized to form EDDP. A second N-demethylation
reaction occurs on EDDP to form EMDP (Sullivan & Due, 1973; Oda & Kharasch, 2001; Ferrari
et al., 2004; Nanovskaya et al., 2004; DePriest, Puet, Holt, Roberts, & Cone, 2015). An alternate
metabolic pathway in the formation of EMDP is a CYP mediated N-demethlyation of
normethadone to form dinormethadone, which is then spontaneously cyclized to EMDP (Lemke
et al., 2012). In a minor biotransformation pathway, the keto group of methadone is reduced by
alcohol dehydrogenase to form methadol, which can be N-demethylated to form normethadol.
The inactive (S)-methadone produces active metabolites of -l-methadol and -l-normethadol,
which have analgesic properties comparable to (R)-methadone. (R)-Methadone, on the otherhand, is metabolized to biologically inactive metabolites of d-methadol and d-normethadol
(Sullivan & Due, 1973; Anggård et al., 1975; Lemke et al., 2012).
Methadone’s long ranging half-life can be partially attributed to the extreme
interindividual pharmacokinetics and its stereoselective metabolism (Leshner, 1997; Boulton,
Arnaud, & DeVane, 2001). (S)-Methadone exhibits a significantly shorter elimination half-life
than (R)-methadone (Kristensen et al., 1996; DePriest et al., 2015). Inherited polymorphisms in
CYPs have the potential to affect the metabolic rate of methadone in a stereoselective manner.
The following sections will discuss the role of CYP SNPs in methadone metabolism and its
consequences on biological activity.
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1.3 Cytochrome P450 (CYP)
There are approximately 57 active human CYP genes grouped into 18 families and 44
subfamilies. Only 12 CYP enzymes, which belong to the CYP1, CYP2, or CYP3 families, are of
major importance and responsible for the metabolism of more than 95% of therapeutic drugs
(Wang & Tompkins, 2008; Wang, Li, & Zhou, 2009; Zanger & Schwab, 2013). The involvement
and contribution of SNPs is inadequately understood in drug biotransformation, but are known to
play a vital role in the differences in patient outcome and the development of personalized
medicine (Solus et al., 2004). SNPs can cause a loss of function mutation, in which the splicing,
expression, or transcription of the CYP gene is decreased or the protein structure is altered.
Alternatively, gain of function mutations may also occur, resulting in an increased substrate
turnover due to an increased number of functional gene copies, as well as variations in the
promotor or amino acids (Johansson & Ingelman-Sundberg, 2008; Sadee et al., 2011; Zanger &
Schwab, 2013). SNPs may be responsible for determining metabolic phenotype – ultra-rapid
metabolizers (UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor
metabolizers (PMs) – and the binding affinity to CYPs, all while affecting the half-life, as well as
the therapeutic and detrimental effects of methadone.
1.3.1 CYP1 Family
The CYP1 family consists of two subfamilies, encompassing three functional genes,
CYP1A1, 1A2, and 1B1. CYP1A1 and CYP1B1 enzymes are mainly expressed extra-hepatically,
whereas CYP1A2 accounts for 4-16% of the hepatic CYPs and is responsible for 8-10% of the
drugs metabolized by CYP isoforms, including methadone (Daly, 2004; McGraw & Waller,
2012; Zanger & Schwab, 2013).

9

The interindividual variations in the mRNA and protein expression levels of CYP1A2
range from 15-40 fold, and a 40-130 fold interindividual difference in activity (Zhou, Liu, &
Chowbay, 2009). To date, there are 192 genetic variants in CYP1A2 (Fokkema et al., 2011;
Fokkema & den Dunnen, 2017). An in silico study, by Wang et al. (2009), found 31
nonsynonymous SNPs, of which 24 were predicted to be deleterious by the SIFT and PolyPhen
algorithms. (S)-Methadone is marginally metabolized by CYP1A2 (Zhou et al., 2009; Chang et
al., 2011). However, results of an in vitro study, conducted by Wang and DeVane (2003), show
neither the depletion of (R)- and (S)-methadone, nor the formation of EDDP by recombinant
CYP1A2. Genetic variations in CYP1A2 did not affect or had little influence on the plasma
concentrations of methadone and EDDP (Fredheim et al., 2009; Zhou et al., 2009; Chang et al.,
2011). Additionally, Crettol et al. (2006) observed CYP1A2*1F did not influence (R)-, (S)-, or
(R,S)-methadone at the peak or trough levels in 245 MMT patients (96% white) (Table 1). Based
on the current studies, CYP1A2 SNPs have not been shown to impact the metabolism of
methadone.
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Alleles

dbSNP ID†

CYP1A2*1F

rs762551

CYP2B6*2
CYP2B6*4

Effect and key amino acid
substitution (if any)

rs8192709
rs2279343

Key sequence
change‡
intron 1, c.-9154C>A
c.64C>T
c.785A>G

CYP2B6*5

rs3211371

c.1459C>T

R487C

CYP2B6*6

rs2279343
rs3745274

c.785A>G
c.516G>T

K262R
Q172H

CYP2B6*9

rs3745274

c.516G>T

Q172H

CYP2B6*11

rs35303484

c.136A>G

M46V

CYP2B6
3’UTR
CYP2B6
3’UTR
CYP2B6
intron 1
CYP2B6
intron 5
CYP2C9*2

rs707265

c.*1355A>G

rs1038376
rs10403955

3’UTR,
c.*1277A>T
c.172-468T>G

rs2279345

c.923-197T>C

rs1799853

c.430C>T

Effect on enzyme activity§
No influence on (R)-, (S)-, or (R,S)-MTD
levels at trough or peak
 [(R,S)-MTD]/[EDDP] ratio
 (R,S)-MTD plasma levels
 (R,S)-MTD plasma levels
 MTD clearance
 (R)- and (S)-MTD N-demethylation
 (S)-MTD plasma levels
 (S)-MTD clearance
No effect on MTD clearance
 (R,S)-MTD plasma levels
 (S)- and (R,S)-MTD plasma levels
 MTD/Dose plasma ratio
 (R)- and (S)-MTD N-demethylation
 MTD clearance
 (R,S)-MTD plasma levels
 [(S)-MTD/MTD Dose] plasma ratio
 (R)- and (S)-MTD N-demethylation
 (S)-MTD clearance
 (S)-MTD plasma levels
 (S)-MTD clearance
 [(S)-MTD/MTD Dose] plasma ratio
 (S)-MTD clearance
 [(S)-MTD/MTD Dose] plasma ratio
 (S)-MTD clearance
 [(S)-MTD/MTD Dose] plasma ratio
 (S)-MTD clearance
 [(S)-MTD/MTD Dose] plasma ratio
 (S)-MTD clearance
No effect on MTD plasma levels

R22C
K262R

R144C
11

Alleles

dbSNP ID†

Key sequence
change‡

Effect and key amino acid
substitution (if any)

CYP2C9*3

rs1057910

c.1075A>C

I359L

CYP2C19*2

rs4244285

c.681G>A

I331V; splicing defect

CYP2C19*3

rs4986893

c.636G>A

W212X; stop codon

CYP3A4*1B

rs2740574

CYP3A5*3

rs776746

5’UTR,
c.-392A>G
5’UTR,
c.219-237A>G

Splicing defect

Effect on enzyme activity§
 MTD/ Dose plasma ratio
No effect on MTD plasma levels
 MTD/Dose plasma ratio
No effect on MTD plasma levels
 (R)-MTD plasma levels
 MTD/Dose plasma ratio
 EDDP plasma levels
No effect on MTD plasma levels
 MTD/Dose plasma ratio
 (S)-MTD plasma levels
No effect on MTD plasma levels
 MTD metabolism (*1/*3 carrier)
 MTD/Dose plasma ratio (*3/*3)

Table 1: Cytochrome P450 Single Nucleotide Polymorphisms Relevant to Methadone Metabolism
†
National Center for Biotechnology Information (NCBI) dbSNP (NCBI Resource Coordinators, 2016)
‡
Location of sequence change on mRNA for the respective CYP NM accession number (NCBI Resource Coordinators, 2016)
§
(Crettol et al., 2005; Crettol et al., 2006; De Fazio et al., 2008; Fonseca et al., 2011; Wang et al., 2011; Dobrinas et al., 2013; Gadel
et al., 2013; Kharasch & Stubbert, 2013; Lee et al., 2013; Levran et al., 2013; Wang et al., 2013; Carlquist et al., 2015; Gadel et al.,
2015; Kharasch et al., 2015; Ahmad et al., 2017; Kringen et al., 2017)
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee (Zhou et al., 2017)
CYP, cytochrome P450; MTD, methadone; EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine; UTR, untranslated region.
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1.3.2 CYP2 Family
The CYP2 family represents about 30% of human CYP isoforms, making it the largest
CYP family (Kim et al., 2015; Daly, 2016). The liver is comprised of five drug metabolizing
CYP2 subfamilies (A-E), of which, the most pharmacologically important genes display the
highest levels of polymorphism (Zanger & Schwab, 2013; Solus et al., 2004). Methadone is
metabolized by several members of the CYP2 family: 2B6, 2C8, 2C9, 2C18, 2C19, and 2D6.
1.3.2.1 CYP2B
CYP2B6 has a 1-10% contribution to the total hepatic CYP pool, accounting for the
metabolism of about 7-8% of pharmaceutical drugs (Zhou et al., 2009; Zanger & Schwab, 2013).
Despite this enzyme’s relatively low involvement in drug metabolism, CYP2B6 is the
predominant determinant involved in the N-demethylation of methadone and clearance. CYP2B6
also displays stereoselectivity towards (S)-methadone (Chang et al., 2011; Kharasch & Stubbert,
2013). CYP2B6 is one of the most polymorphic genes, having 74 allelic variants and 38 protein
variants, which affect catalytic activity, transcriptional regulation, and splicing. The variants also
affect mRNA and protein expression, exhibiting nearly 300 fold interindividual variability
(Fokkema et al., 2011; Zanger & Klein, 2013; Zanger & Schwab, 2013; Ingelman-Sundberg,
2017; Zhou, Ingelman-Sundberg, & Lauschke, 2017; Fokkema & den Dunnen, 2018a).
CYP2B6 SNPs can alter the metabolic ratios of [methadone]/[EDDP]. A significant
decrease in the metabolic ratio was observed in individuals carrying the CYP2B6*2 allele,
suggesting a role in an increased rate of metabolism. The data should be interpreted with caution
because the subjects heterozygous for the variant only had a sample size of two (Ahmad, Sabet,
Primerano, Richards-Waugh, & Rankin, 2017). A bioinformatics study also predicted CYP2B6*2
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to alter the metabolic phenotype as determined by both the SIFT and PolyPhen algorithms
(Wang et al., 2009).
Lee et al. (2013) studied the influence of CYP2B6*4 on methadone plasma
concentrations in 178 MMT patients in Taiwan. The study indicated an increase in (R,S)methadone plasma levels in individuals homozygous for CYP2B6*4. The results were consistent
with the Levran et al. (2013) study of 74 Israeli MMT patients; though neither study showed any
significant differences in the increase in (R,S)-methadone plasma levels. On the other hand,
Kharasch and colleagues (Kharasch, Regina, Blood, & Friedel, 2015) observed CYP2B6*4
carriers had a significant decrease in (R)-, (S)-, and (R,S)- methadone plasma levels, with
increased methadone metabolism and clearance. It is important to note that one of the limitations
to this study was the small sample size (n=4). Gadel and colleagues (2015) demonstrated an
increase in N-demethylation of methadone by CYP2B6*4 in an in vitro study, supporting the
findings of Kharasch et al. (2015).
CYP2B6*5 shows contradicting data in its involvement in methadone clearance and
plasma concentrations. In a genotyping study of methadone-only overdoses in 125 Caucasians,
CYP2B6*5 was linked to a significant increase in (R,S)-methadone plasma levels (Ahmad et al.,
2017). In a study cohort consisting of 35 individuals with low (S)-methadone levels, CYP2B6*5
was overrepresented, indicating an increased CYP2B6 activity (Dobrinas et al., 2013). The
methadone plasma concentration of two individuals genotyped for homozygosity in CYP2B6*5
appeared to remain unaltered when compared to that of the wild type CYP2B6*1 (Kharasch et
al., 2015).
CYP2B6*6 is a haplotype consisting of two nonsynonymous variants, CYP2B6*4 and
CYP2B6*9. Numerous papers indicate an increase in (R,S)- and (S)-methadone plasma levels in
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CYP2B6*6/*6 individuals (Crettol et al., 2005; Crettol et al., 2006; Kharasch & Stubbert, 2013;
Kharasch et al., 2015; Kringen et al., 2017). Gadel and colleagues (Gadel, Crafford, Regina, &
Kharach, 2013) and Kharasch et al. (2015) have also demonstrated a decrease in methadone Ndemethylation and decreased methadone clearance, respectively. An in vitro study found SNPs
CYP2B6*6 and CYP2B6*9 to be catalytically deficient in EDDP formation (Gadel, Friedel, &
Kharasch, 2015). Furthermore, increased (R,S)-methadone plasma levels were observed in 74
Israeli MMT patients homozygous for the CYP2B6*9 SNP, though the increase was not
statistically significant (Levran et al., 2013). A significant increase in plasma concentrations and
a decrease in (S)-methadone metabolism was observed in 366 Taiwanese MMT patients
encompassing the CYP2B6*9 SNP (Wang et al., 2011). The studies observing the SNPs of the
haplotype CYP2B6*6 suggest that the diminishing metabolic activity of CYP2B6*6/*6 is
credited to the c.516G>T variant of CYP2B6*9.
Dobrinas et al. (2013) observed an overrepresentation of CYP2B6*11 polymorphism in a
high (S)-methadone level group of MMT patients, indicating a decline in CYP2B6 activity.
Wang et al. (2011) examined polymorphisms in the intronic and 3’-untranslated region (UTR)
regions of CYP2B6, and demonstrated the SNPs rs707265, rs2279345, rs1038376, and
rs10403955 all correspond to increased [(S)-methadone/methadone dose] plasma ratios, and
decreased (S)-methadone clearance (Table 1). The SNPs investigated in this section demonstrate
a compelling link to the importance of genetic variations in CYP2B6 and altered metabolism of
methadone.
1.3.2.2 CYP2C
The CYP2C subfamily consists of four genes, CYP2C8, 2C9, 2C18, and 2C19. The CYPs
from these genes all contribute to the metabolism of methadone (Iribarne et al., 1996; Crettol et
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al., 2005; Chang et al., 2011; Fonseca et al., 2011). CYP2C9 is the highest expressed isozyme of
the four in liver, while CYP2C8 and CYP2C19 are expressed at 2 and 10 fold lower levels than
CYP2C9 (Zanger & Schwab, 2013). CYP2C18 is expressed primarily in the skin (Zhou et al.,
2009). CYP2C19 comprises 16% of the CYP2C family and metabolizes methadone to a greater
extent, as compared to the CYP2C8, 2C9, and 2C18 isozymes (Dinis-Oliveira, 2016). The
CYP2C family demonstrates stereoselectivity in methadone metabolism, where CYP2C8 and
2C19 predominately metabolize (R)-methadone, while CYP2C18 primarily metabolizes (S)methadone.
Currently, there are no polymorphic studies on CYP2C8 and 2C18 and their role in
methadone metabolism. This is not surprising for CYP2C18, where only 8 variants have been
reported to date (Fokkema et al., 2011; Fokkema & den Dunnen, 2015a). There are 97 genetic
variants observed in CYP2C8 (Fokkema et al., 2011; Fokkema & den Dunnen, 2015b), which
has a minor role in the metabolism of methadone, probably contributing to the dearth of studies
in the corresponding SNPs.
Although CYP2C9 exhibits 378 genetic variants and 2C19 has 236 reported genetic
variants (Fokkema et al., 2011; Fokkema & den Dunnen, 2018b; Fokkema & den Dunnen,
2019), only *2 and *3 have been examined for their respective CYP isozymes. Results from
three separate studies showed no effect on methadone plasma levels with CYP2C9*2 and
CYP2C9*3 genotypes in Caucasians (Crettol et al., 2005; Crettol et al., 2006; Fonseca et al.,
2011). A significant increase in methadone serum concentrations/dose ratio with heterozygous
carriers of CYP2C9*2 and CYP2C9*3 SNPs was observed in a study in Norway. Similar results
were seen for the homozygous CYP2C9*2 and CYP2C9*3 individuals, albeit, there were no
significant differences in methadone serum concentrations/dose ratios (Kringen et al., 2017).
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In studies by Crettol et al. (2005; 2006), CYP2C19*2 and CYP2C19*3 were also found to
lack an effect on methadone plasma levels. A study of 366 Taiwanese MMT patients showed
homozygous carriers of CYP2C19*2 were associated with a significant increase in (R)methadone levels. Patients homozygous for CYP2C19*3 also tended to exhibit an increase in
(R)-methadone levels, although the data was not significantly different (Wang et al., 2013).
Carlquist et al. (2015) observed an increase in the plasma levels of EDDP with CYP2C19*2 in
25 MMT patients (20 Caucasian, 4 Hispanic, and 1 African American), indicating an increase in
methadone metabolism. Kringen et al. (2017) noticed, in a Norwegian population, individuals
homozygous and heterozygous carriers for CYP2C19*2 and CYP2C19*3 had an increase in
methadone serum concentration/dose ratio, with significant differences seen only in
heterozygotes. The contradicting results in the CYP2C19 variants between these studies could be
attributed to the ethnicity of the patients, where the frequencies of both CYP2C19*2 and
CYP2C19*3 are higher in Asians than Caucasians (Table 1).
1.3.2.3 CYP2D
The CYP2D subfamily consists of only one protein coding gene, CYP2D6, which
accounts for 2-5% of the hepatic CYP composition and ~25% of pharmacological drug
metabolism (Zanger & Schwab, 2013; NCBI Resource Coordinators, 2016). CYP2D6
metabolizes both enantiomers of methadone, with a slightly greater propensity towards (S)methadone (Wang & DeVane, 2003; Chang et al., 2011). Unlike SNPs in other CYP genes,
CYP2D6 phenotype is determined by allele combinations. PMs consist of two non-functional
alleles, IMs are comprised of two decreased activity alleles, EMs have at least one functional
allele, and UMs encompass more than one functional allele and/or an allele with a promoter
mutation (Fonseca et al., 2011). The major and most common mutation alleles are CYP2D6*3,
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*4, *5, and *6, accounting for 93-97% of alleles among PM phenotypes (Eap et al., 2001;
Trescot & Faynboym, 2014). CYP2D6*1 and CYP2D6*2 alleles represent normal functional
activity.
In a 2001 study conducted by Eap et al. (2001), CYP2D6 phenotypes had a significant
influence on the (R)-, (S)-, and (R,S)-methadone blood concentrations, where higher
concentrations were observed in PMs (CYP2D6*4/*4, *4/*3, *4/*6) and lower concentrations
were measured in UMs (CYP2D6*1/*1). Similarly, Crettol and colleagues (2006), observed a 0.5
fold decrease in (S)-methadone and 0.7 fold decrease in (R)-methadone plasma levels in UMs
(CYP2D6*1/*1xN) when compared to the EM/IM (CYP2D6*1/*3, *1/*4, *1/*5, *1/*6) group. In
another study, the PM, IM, and EM phenotypes, representing alleles CYP2D6*1, *1xN, *2, *3,
*4, *4xN, *5, *6, *9, *10, *16, *28, *33, and *41, did not impact the clearance of (R)-, (S)-, or
(R,S)-methadone (Coller et al., 2007). CYP2D6*3, *4, *5, *6, *7, and *8 are non-functional
variants, and CYP2D6*9, *10, and *41 have a decrease in function (Coller et al., 2007). Fonseca
et al. (2011) observed EM patients received significantly lower doses of methadone as compared
to UMs. It was also concluded that, contradictory to the phenotypes, UM (CYP2D6*1xN, *2xN)
patients had significantly higher methadone plasma levels than EM (CYP2D6*1, *2, *3, *6, *35)
and PM (CYP2D6*4/*4) patients. Further investigations on the CYP2D6 alleles need to be
conducted to get a clearer understanding of their significance. The relationship between CYP2D6
allelic variants and phenotypic expression is depicted in Table 2.
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Alleles

dbSNP ID†

Key sequence
change‡

Effect and key amino acid
substitution (if any)

Effect on enzyme activity§ Phenotype
Wild type
Duplication of gene
Multiduplication of gene
N active genes
 activity
Normal activity
Duplication of gene
Multiduplication of gene
N active genes
 activity
Defective allele
Defective allele

EM

CYP2D6*4xN

Defective allele
Multiduplication of gene

PM

CYP2D6*5

Deletion of entire CYP2D6
gene
Defective allele
Defective allele
Defective allele

PM

Impaired function
Impaired function

IM
IM

CYP2D6*1
CYP2D6*1xN

CYP2D6*2

rs16947
rs1135840

c.886C>T
c.1457G>C

R296C
S486T

CYP2D6*2xN

CYP2D6*3
CYP2D6*4

CYP2D6*6
CYP2D6*7
CYP2D6*8

CYP2D6*9
CYP2D6*10
CYP2D6*16

rs3574686
rs1065852
rs28371703
rs28371704
rs3892097
rs1135840

rs5030655
rs5030867
rs5030865
rs16947
rs1135840
rs5030656
rs1065852
rs1135840

c.775delA
c.100C>T
c.271C>A
c.281A>G
c.506-1G>A
c.1457G>C

c.454delT
c.971A>C
c.505G>A
c.886C>T
c.1457G>C
c.841_843delAAG
c.100C>T
c.1457G>C
CYP2D7/2D6 hybrid

259Frameshift
P34S
L91M
H94R
Splicing defect
S486T

118Frameshift
H324P
G169R
R296C
S486T
K281del
P34C
S486T
Frameshift; switch region
exon7-intron 8
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UM

EM
UM

PM
PM

PM
PM
PM

PM

Alleles

dbSNP ID†

CYP2D6*17

rs28371706
rs16947
rs1135840
rs78482768
rs16947
rs1135840
rs61736512
rs16947
rs59421388
rs1135840
rs28371717
rs769258
rs16947
rs1135840
rs1065852
rs1135840
rs16947
rs28371725
rs1135840
rs28371696

Key sequence
change‡
c.320C>T
c.886C>T
c.1457G>C
19G>A
c.451C>G
c.886C>T
c.1457G>C
c.406G>A
c.886C>T
c.1012G>A
c.1457G>C
c.709G>T
c.31G>A
c.886C>T
c.1457G>C
c.100C>T
c.1457G>C
c.886C>T
c.985+39G>A
c.1457G>C
c.77G>A

Effect and key amino acid
substitution (if any)
T107I
R296C
S486T
V7M
Q151E
R296C
S486T
V136I
R296C
V338M
S486T
A237S
V11M
R296C
S486T
P34S
S486T
R296C
Splicing defect
S486T
R26H

rs28371710
rs16947
rs1135840

c.463G>A
c.886C>T
c.1457G>C

E155K
R296C
S486T

CYP2D6*28

CYP2D6*29

CYP2D6*33
CYP2D6*35

CYP2D6*36
CYP2D6*41

CYP2D6*43
CYP2D6*45

Effect on enzyme activity§ Phenotype
Impaired function

IM

Unknown

Unknown

Impaired function

IM

Normal activity
Normal activity
Duplication of gene

EM
EM

Defective allele

PM

Impaired function

IM

Normal activity
Duplication of gene
Normal activity
Duplication of gene

EM
EM

Table 2: Cytochrome P450 2D6 and Their Corresponding Activity and Phenotype
†
National Center for Biotechnology Information (NCBI) dbSNP (NCBI Resource Coordinators, 2016)
‡
Location of sequence change on mRNA for the respective CYP NM accession number (NCBI Resource Coordinators, 2016)
§
(Eap et al., 2001; Crettol et al., 2006; Coller et al., 2007; Johansson & Ingelman-Sundberg, 2008; Fonseca et al., 2011)
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee (Zhou et al., 2017)
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CYP, cytochrome P450; del, deletion; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultrarapid metabolizer.
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1.3.3 CYP3 Family
The CYP3 family consists of only one subfamily, CYP3A, and four functional genes,
CYP3A4, 3A5, 3A7, and 3A43. These enzymes play a dominant role in drug metabolism
pathways (~50%). CYP3A4 is the most expressed enzyme in adult liver, while CYP3A7 is
predominantly expressed in fetal liver and is down-regulated after birth. CYP3A5 is
polymorphically expressed in the liver, where alternative splicing results in multiple transcript
variants, exhibiting high and low level proteins (Lamba, Lin, Schuetz, & Thummel, 2012;
Zanger & Schwab, 2013; NCBI Resource Coordinators, 2016).
Methadone has been shown to be N-demethylated by CYP3A4, 3A5, and 3A7 in a
nonstereoselective manner (Foster, Somogyi, & Bochner, 1999; Chang et al., 2011). CYP3A4
and CYP3A5 have relatively low numbers of genetic variants, suggesting minor clinical
importance in the clearance of their respective substrates (Zhou et al., 2009; Levran et al., 2013).
This observation would be in line with the lack of polymorphic studies found for CYP3A and
their role in methadone metabolism. However, in one study, the allelic frequency of CYP3A4*1B
in 245 MMT patients (96% white) was observed and correlated with an increase in methadone
plasma levels (Crettol et al., 2006). In the same study, the study cohort was genotyped for the
deficient allele CYP3A5*3. The plasma levels of methadone were not influenced by the CYP3A5
genotype. It is also interesting to note that there was a strong linkage between CYP3A4*1B and
CYP3A5*3 genotypes (Crettol et al., 2006). Similar results were observed by Fonseca, et al.
(2011), where the genetic polymorphism of CYP3A5 did not influence methadone plasma levels.
One case report of a 25-year old male in a MMT program showed extensive metabolism of
methadone to EDDP. The subject was found to be heterozygous for CYP3A5*1 (CYP3A5*1/*3)
(De Fazio, Gallelli, De Siena, De Sarro, & Scordo, 2008). A large amount of CYP3A5 is
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expressed in individuals carrying at least one CYP3A5*1 allele (De Fazio et al., 2008). In a
recent study of 155 serum samples and 62 patients, homozygous carriers of CYP3A5*3
demonstrated a significant increase in methadone serum concentration/dose ratio, indicating a
decrease in methadone clearance (Kringen et al., 2017) (Table 1).
1.4 Consequences of Altered Methadone Metabolism
Polymorphisms in genes encoding CYP enzymes have the potential to shift their
metabolic capacity or change the substrate specificity of the enzyme, eliciting variable
consequences in drug treatment (Jurica & Sulcova, 2012; Tamási & Falus, 2012). These changes
can be crucial in the therapeutic potency of methadone. The main metabolic pathway of
methadone involves the N-demethylation by hepatic CYPs into the primary metabolite, EDDP.
Changes in the rate of EDDP formation could influence the pharmacodynamics of methadone.
CYP2B6*4 was the only SNP that was found to increase the clearance of methadone by
the N-demethylation of both (R)- and (S)-methadone (Gadel et al., 2015; Kharasch et al., 2015).
In turn, there would be a decrease in the disposition of (R,S)-methadone, reducing the
pharmacological effect of methadone and inducing withdrawal symptoms. Individuals with this
SNP may require a higher dose of methadone.
Several SNPs were found to increase the methadone plasma concentration due to a
decrease in the metabolic activity of the CYPs. Three independent studies collectively
demonstrated elevated plasma levels of (R,S)- and (S)-methadone with diminishing Ndemethylation of (R)- and (S)-methadone due to CYP2B6*2, *9 and *11 (Wang et al., 2011;
Dobrinas et al., 2013; Levran et al., 2013; Gadel et al., 2015; Ahmad et al., 2017). CYP2B6*6 is
a haplotype consisting of both CYP2B6*4 and CYP2B6*9 variants. Carriers of CYP2B6*6/*6
had diminished methadone metabolism and clearance, hence, an increase in methadone levels.
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This activity is credited to the CYP2B6*9 SNP, where individuals with CYP2B6*4/*6 haplotype
did not observe the metabolic inhibition (Crettol et al., 2005; Crettol et al., 2006; Gadel et al.,
2013; Kharasch & Stubbert, 2013; Gadel et al., 2015; Kharasch et al., 2015; Kringen et al.,
2017). Mutations located in the UTR and intronic regions are also relevant in the
biotransformation of methadone. Table 1 shows the four SNPs in the UTR and intronic regions
linked to a decreased clearance and increased concentration of methadone (Wang et al., 2011).
CYP2B6 influences the metabolism of (S)- methadone and, to a far lesser extent, (R)-methadone.
Individuals with the genotypes mentioned above, particularly CYP2B6*6/*6, have a greater risk
of suffering torsades de pointes and sudden death. A lower dose of methadone may be required
for treatment for individuals with these variants.
Reduced metabolism by CYP2C19 can lead to increased plasma concentrations of
methadone, specifically (R)-methadone, which can potentiate depressed ventilation manifesting
as a potentially fatal respiratory depression. Both CYP2C19*2 and CYP2C19*3 were associated
with elevated methadone plasma concentrations (Wang et al., 2013; Kringen et al., 2017).
However, these results could be variable in different ethnic groups.
CYP2D6 and CYP3A4/5 metabolize both enantiomers of methadone, though CYP2D6
has a slightly greater preference towards (S)-methadone. Decreased metabolism by these CYPs
may heighten either detrimental effect due to augmented levels of methadone. CYP3A4*1B has
been shown to increase (S)-methadone plasma levels (Crettol et al., 2006), which can lead to
cardiotoxic effects. In a study of 136 Caucasian individuals who died of methadone-only
overdosing, an enrichment was observed in the CYP3A4*1B SNP (Richards-Waugh, Primerano,
Dementieva, Kraner, & Rankin, 2014). CYP3A5*3 is a common SNP with high frequency in the
Caucasian population, where a splicing defect causes a loss of function of the CYP3A5 enzyme
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(McGraw & Waller, 2012). This loss of function is exemplified in a couple of studies where the
methadone plasma levels are elevated in CYP3A5*3/*3 individuals, while metabolism is
increased and plasma levels are decreased in individuals carrying at least one copy of CYP3A5*1
(De Fazio et al., 2008; Gadel et al., 2013). The effects of SNPs located on the CYP2D6 gene is
slightly more complicated. CYP2D6-dependent metabolism of methadone has been studied
based on the phenotypic variability determined by a combination of SNPs on the CYP2D6 gene.
There have not been any clear implications on the relationship between CYP2D6 SNPs and
methadone metabolism and their role on the pharmacokinetics and pharmacodynamics of
methadone.
Since methadone is metabolized by a number of CYPs, a combination of any of the
SNPs, within or between genes, can have varying effects on the pharmacological response of
methadone treatment. A genome-wide pharmacogenomic study showed two CYP2B6 haplotypes
of rs8100458, rs7250601, rs7250991, rs11882424, rs8192719, and rs10853744 (T-A-A-T-C-G
and T-C-C-T-T-T) accounted for the variation in (S)-methadone plasma levels (Yang et al.,
2016). In order to understand the complexity of the effects of CYP SNPs on methadone
pharmacokinetics and pharmacodynamics, inclusion of additional gene variants and haplotype
variants is required. Though SNPs influence only part of methadone pharmacology, the impact
of genetic variations can be compounded by drug interactions, environmental factors, sex, health,
and other nongenetic factors. Co-administration of methadone with respiratory depressants, such
as other opioids, alcohol, or benzodiazepines, may lead to a greater detrimental effect. Likewise,
individuals with reduced liver function (e.g. cirrhosis) could have a reduced capacity to
metabolize methadone.
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1.5 Conclusions
Methadone is currently used as a treatment and maintenance therapy for opioid addiction
and as an analgesic for severe chronic pain. The wide-ranging half-life of methadone may result
in some individuals having higher than normal therapeutic levels leading to negative,
detrimental, and fatal side effects. Elevated (R)-methadone levels may lead to respiratory
depression, while an increase in plasma levels of (S)-methadone may lead to severe cardiac
arrhythmias. A significant portion of opioid-related deaths have been contributed to the use of
prescription methadone for pain management. The pharmacogenetics of an individual possesses
the ability to affect the pharmacokinetics and pharmacodynamics of methadone. SNPs located on
CYP genes shift the metabolic capacity or change the substrate specificity of the CYP enzyme,
affecting the metabolism of methadone. SNPs CYP2B6*6, *9, *11, CYP2C19*2, *3,
CYP3A4*1B, and CYP3A5*3 result in increased methadone plasma concentrations, decreased Ndemethylation, and decreased methadone clearance. Since CYP2B6 is the major determinant of
methadone clearance, CYP2B6*6/*6 is of particular interest. Homozygous carriers of
CYP2B6*6/*6 expressed diminished methadone metabolism and clearance, thus these
individuals have a greater propensity for detrimental adverse effects. However, CYP2B6*4
demonstrated an increase in N-demethylation and methadone clearance. A better understanding
of the role of CYP SNPs in methadone metabolism can improve the proper therapeutic dosing
for methadone, patient outcome, and the development of individualized medicine.
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The information in this chapter has been published in Journal of Analytical Toxicology.
Ahmad, T., Sabet, S., Primerano, D. A., Richards-Waugh, L. L., & Rankin, G. O. (2017, May).
Tell-tale SNPs: The role of CYP2B6 in methadone fatalities. Journal of Analytical Toxicology,
41(4), 325-333. doi:10.1093/jat/bkw135

Reprinting for dissertation is part of the author’s rights and permission is not required from
Oxford Academic, the copyright holder.

Taha Ahmad1, Samie Sabet1, Donald A. Primerano1, Lauren L. Richards-Waugh2, and Gary O.
Rankin1,*

1

Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University,

1700 Third Avenue, Huntington, WV 25755, USA, and 2Forensic Science Department, Marshall
University, 1401 Forensic Science Drive, Huntington, WV 25701, USA

*Corresponding author at: Department of Biomedical Sciences, Joan C. Edwards School of
Medicine, BBSC-435F, Marshall University, 1700 Third Avenue, Huntington, WV 25755, USA.
E-mail address: rankin@marshall.edu (G.O. Rankin).

27

Abstract
Cytochrome P450 (CYP) enzyme 2B6 plays a significant role in the stereoselective
metabolism of (S)- methadone to 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine, an inactive
methadone metabolite. Elevated (S)-methadone can cause cardiotoxicity by prolonging the QT
interval of the heart’s electrical cycle. Large interindividual variability of methadone
pharmacokinetics causes discordance in the relationship between dose, plasma concentrations
and side effects. The purpose of this study was to determine if one or more single nucleotide
polymorphisms (SNPs) located within the CYP2B6 gene contributes to a poor metabolizer
phenotype for methadone in these fatal cases. The genetic analysis was conducted on 125
Caucasian methadone-only fatalities obtained from the West Virginia and Kentucky Offices of
the Chief Medical Examiner. The frequency of eight exonic and intronic SNPs (rs2279344,
rs3211371, rs3745274, rs4803419, rs8192709, rs8192719, rs12721655 and rs35979566) was
determined. The frequencies of SNPs rs3745274 (*9, c.516G>T, Q172H), and rs8192719
(21563C>T) were enhanced in the methadone-only group. Higher blood methadone
concentrations were observed in individuals who were genotyped homozygous for SNP
rs3211371 (*5, c.1459C>T, R487C). These results indicate that these three CYP2B6 SNPs are
associated with methadone fatalities.
2.1 Introduction
Initially discovered and developed in Germany during World War II, methadone is a
synthetic MOR agonist that has been used as an analgesic alternative to morphine when it was
difficult to obtain (Lugo et al., 2005; Lisberg & Scheinmann, 2013; Somogyi et al., 2014). In
1965, methadone was introduced as a treatment regimen of opioid drug dependence or
withdrawal symptoms in patients (Somogyi et al., 2014). Nearly a decade later, in 1976,
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physicians were given permission to prescribe methadone as an analgesic to maintain adequate
pain control (Toombs & Kral, 2005), for malignant pain in cancer patients and non-malignant
pain that continues beyond the normal course of a disease or injury (Taylor et al., 2000; Jackman
et al., 2008).
Methadone is clinically available in the USA only as a racemic mixture containing equal
amounts of the (R)- and (S)-methadone enantiomers (Gaertner et al., 2008; Kapur et al., 2011;
McCance-Katz, 2011). Each enantiomer has specific pharmacodynamic properties. The analgesic
properties of methadone are attributed to the (R)-enantiomer, which has a 10-fold greater affinity
for the MOR (Kristensen, Christensen, & Christrup, 1995; Foster et al., 1999) and is 8 – 50 times
more potent than (S)-methadone (Lugo et al., 2005). As concentrations of (R)-methadone
increase above therapeutic levels, negative side effects on MORs in the brainstem respiratory
centers can be potentiated, thus mediating respiratory depression (Mitchell et al., 2004;
Silverman et al., 2009). On the other hand, elevated (S)-methadone causes cardiotoxicity by
prolonging the QT interval and subsequently leads to torsade de pointes by blocking the voltagegated potassium channel of the human ether-a-go-go related gene (hERG) (Eap et al., 2007;
Dobrinas et al., 2013). This stereoselective cardiotoxicity is attributed to (S)-methadone being
3.5 times more potent than (R)- methadone in blocking the hERG channel (Eap et al., 2007;
Ansermot et al., 2010; Dobrinas et al., 2013).
Methadone metabolism occurs primarily through the route of oxidative
biotransformation. The principle metabolite, EDDP, is formed during metabolism through an Ndemethylation reaction followed by spontaneous cyclization (Moody et al., 1997; Foster et al.,
1999; Ferrari et al., 2004; Nanovskaya et al., 2004; Lehotay et al., 2005). EDDP is further
metabolized to EMDP. Neither of these metabolites is pharmacologically active (Oda &
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Kharasch, 2001; Ferrari et al., 2004; Nanovskaya et al., 2004). CYP enzymes in the liver are
responsible for the metabolism of methadone, which undergoes stereoselective N-demethylation
(Lugo et al., 2005). CYP3A4, 2B6 and 2C19 account for majority of the conversion of
methadone to EDDP and other inactive metabolites, with minor contributions from CYP2C8,
2D6, 2D8, 2C18 and 3A7 (Wang & DeVane, 2003; Chang et al., 2011; Kapur et al., 2011). (R)Methadone is preferentially metabolized by CYP2C8 and CYP2C19, whereas (S)-methadone is
primarily metabolized by CYP2B6 and CYP2D6. CYP3A4 has no stereoselectivity,
metabolizing both enantiomers (Chang et al., 2011; Kapur et al., 2011).
Methadone is a difficult medication to safely prescribe due to extreme variability in
interindividual pharmacokinetics, making the relationship between dose, plasma concentrations
and effects difficult to define (Leshner, 1997; Boulton et al., 2001). This methadone plasma
variability increases the risk of an unexpected death. According to the most recent CDC report
(2012), methadone accounts for >30% of prescription opioid deaths, while it only represents 2%
of all opioid prescriptions. Much of the interindividual variability in methadone
pharmacokinetics may be due to genetic variations within the genes encoding CYP enzymes
responsible for the metabolism of methadone (Li et al., 2008).
SNPs are the most common form of genetic variation in the CYP genes (Risch, 2000;
Daly, 2004). CYP2B6 is a highly polymorphic gene with 74 allelic variants equating to 38
protein variants and a series of subvariants, designated *1B to *38 (Zhou et al., 2009; McGraw &
Waller, 2012; Ingelman-Sundberg, 2017; Fokkema & den Dunnen, 2018a). These SNPs are
thought to play a role in interindividual and interethnic differences in the response of drug
metabolism by CYP2B6 (Zhou et al., 2009). It is known that CYP2B6 plays a major role in the
biotransformation of many clinically important drugs, such as selegiline (Watanabe et al., 2010),
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bupropion (Lang et al., 2004), efavirenz (Holzinger et al., 2012), artemether (Honda et al., 2011)
and methadone (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et al., 2013). These studies
demonstrated that some allelic variants (e.g., rs2279344, rs3211371, rs3745274, rs4803419,
rs8192709, rs8192719, rs12721655 and rs35979566) lead to a decreased expression or decreased
enzyme activity of CYP2B6.
Several pharmacogenetic studies have been previously conducted involving methadonerelated deaths or patients in a MMT program. However, these studies did not include cases
where only methadone was detected; rather, those studies used mixed drug cases and/or had
small sample sizes (Crettol et al., 2005; Eap et al., 2007; Dobrinas et al., 2013). The present work
is unique because we genotyped and analyzed CYP2B6 variants in 125 Caucasians involved with
methadone-only fatalities. Eight key SNP variants present in the Caucasian population were
genotyped to test for enrichment. The analyses performed in this study were aimed to provide
insight into the association of CYP2B6 SNPs in individuals who succumb to methadone
intoxication in the methadone-only cases. Because exonic variants cause amino acid
substitutions, which can affect the enzymatic activity and intronic regions, are responsible for
splicing, frameshifting and binding microRNAs, SNPs in both of these regions were examined to
determine their association with methadone toxicity in the study population.
2.2 Material and Methods
2.2.1 Chemicals and Enzymes
QIAamp DNA Micro extraction kits were purchased from Qiagen (Valencia, CA, USA).
Absolute ethanol was purchased from Pharmco-Aaper (Shelbyville, KY, USA). MicroAmp
Optical 96-well Reaction Plates, 96-well Fast PCR Plates, MicroAmp Optical Adhesive Film,
TaqMan Universal PCR Master Mix No AmpErase UNG and TaqMan SNP Genotyping Assays
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were purchased from Life TechnologiesTM (Foster City, CA, USA). Tris base,
ethylenediaminetetraacetic acid (EDTA) and all other reagents were purchased from SigmaAldrich (St. Louis, MO, USA).
2.2.2 Sample Collection
The characteristics of all of the samples used and studied in the paper were described in a
previous study on methadone pharmacogenetics (Richards-Waugh et al., 2014). Briefly, the
cases for this study were derived from fatalities due to methadone occurring from 2003 to 2008
in the Offices of the Chief Medical Examiner (OCMEs) of West Virginia (WV) and Kentucky
(KY). Based on the toxicity criteria, 125 Caucasian cases (78 from WV and 47 from KY) related
to methadone-only fatalities were selected. A control group of 255 cases was obtained from the
WV OCME, in which toxicology immunoassays were negative for amphetamines, barbiturates,
benzodiazepines, buprenorphine, cocaine, methadone, propoxyphene, opiates, oxycodone and
tricyclic antidepressants. Demographic data for the WV cases, along with the number of KY
cases are outlined in Table 3.

WV Cases
KY Cases*
Total Cases
Age Ranges (years)
Mean Age
Males (%)
Females (%)

Methadone-Only Overdoses
78
47
125
1.75 – 58
34.07  11.40
58 (74.4%)
20 (25.6%)

Controls
255
0
255
2 – 88
45.35  18.70
194 (76.1%)
61 (23.9%)

Table 3: Demographic of Study Groups
*
Age and gender were not available for the KY Cases
2.2.3 DNA Extraction
Following the manufacturer’s protocol for dried blood spots, QIAamp DNA Micro
extraction kits were used for the purification of genomic DNA from blood stain cards prepared
by the WV and KY OCMEs. Extractions were performed in triplicate in order to increase overall
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genomic DNA yields; the three DNA solutions were pooled and then concentrated by passage
over a MiniElute column. Extracted DNA was quantitated by absorbance spectrophotometry on a
NanoDrop 1000. Samples were diluted to a concentration of 1.78 ng/µL with Tris-EDTA buffer
to a final volume of 100 µL for use in the SNP genotyping assays. All genomic DNA samples,
initial extractions and 1.78 ng/µL working solutions, were stored at 4°C.
2.2.4 SNP Selection
Eight different SNPs within the CYP2B6 gene were genotyped. Five exonic SNPs,
rs3211371 (*5, c.1459C>T, R487C), rs3745274 (*9, c.516G>T, Q172H), rs8192709 (*2,
c.64C>T, R22C), rs12721655 (*8, c.415A>G, K139E) and rs35979566 (*15, c.1172T>A,
I391N), were selected because they were considered polymorphic in the Caucasian population,
and known to encode non-synonymous amino acid substitutions (Figure 2). The remaining three
SNPs, rs2279344 (18273G>A), rs4803419 (15582C>T) and rs8192719 (21563C>T), were
intronic and had Minor Allele Frequencies (MAFs) of at least 5% (Figure 2).

Figure 2: Location of Exonic and Intronic SNPs within the CYP2B6 Gene
Minor allele frequency in parenthesis.
2.2.5 SNP Genotyping
The following Life TechnologiesTM TaqMan SNP Genotyping kits were used to
determine CYP2B6 genotypes: (i) C__26823974_30 (rs2279344), (ii) C__30634242_40
(rs3211371), (iii) C___7817765_60 (rs3745274), (iv) C___7817764_10 (rs4803419), (v)
C___2818162_20 (rs8192709), (vi) C__22275631_10 (rs8192719), (vii) C__30634236_20
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(rs12721655) and (viii) C__33845840_20 (rs35979566). Real-time polymerase chain reaction
(RT-PCR) and allelic discrimination were carried out in a total volume of a 25 µL reaction,
containing 20 ng of genomic DNA, TaqMan Universal PCR Master Mix No AmpErase UNG
(1X) and a TaqMan SNP Genotyping Assay (1X). PCR parameters were set for polymerase
activation at 95°C for 10 min followed by 50 cycles (rs2279344, rs3211371, rs3745274,
rs4803419 and rs8192709) or 55 cycles (rs8192719) of denaturation at 92°C for 30 s and
annealing/extension for 90 s at 60°C for each SNP on an ABI7000 Sequence Detection System.
SNP rs12721655 and rs35979566 were genotyped on an ABI StepOnePlusTM Instrument using
the RT-PCR parameters of 95°C for 10 min followed by 65 cycles of 92°C for 15 s and 60°C for
90 s. All SNP genotypes were determined using both the auto and manual allele call options on
their respective instrument software.
2.2.6 Statistical Analysis
Allele frequencies for the control and methadone-only groups were calculated based on
the allelic calls for all SNPs in each group. A χ2 test with two degrees of freedom was used to
assess the differences between the MAFs in the control group and the MAFs reported in the
National Center for Biotechnology Information (NCBI) dbSNP database for the Caucasian
population and between the control study group and the methadone-only fatality study group. Pvalues < 0.05 were considered to statistically significant. We also assessed whether genotypic
frequencies for each SNP were in Hardy–Weinberg equilibrium (HWE) using a χ2 test with two
degrees of freedom. When performing the statistical analysis on the blood methadone
concentrations and [methadone]/[EDDP] ratio, the methadone-only group was further divided
into two groups. All 125 fatalities due to methadone were used for the analysis of blood
methadone concentrations, while only the cases obtained from the WV OCME were used for the
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analysis of [methadone]/[EDDP] ratios (the KY OCME did not determine EDDP concentrations,
hence the [methadone]/[EDDP] ratio data were not available). The blood methadone
concentration measurements were conducted by the OCMEs during the toxicological testing, and
therefore, represent both the (R)- and (S)- methadone concentrations combined. The mean,
standard deviation, standard error of the mean (SEM) and unpaired t-test with Welch’s correction
or one-way analysis of variance (ANOVA) with Tukey test correction was used to compare
blood methadone concentrations (mg/L) between homozygotes for the major allele (ancestral),
heterozygotes and homozygotes for the minor allele (variant) in WV/KY methadone-only cases.
The same tests were also performed to compare [methadone]/[EDDP] ratio between ancestral,
heterozygotes and variant alleles in the WV methadone-only cases. One-way ANOVA analyses
were performed only on groups that had a minimum number of two cases for each genotype; an
unpaired t-test with Welch’s correction was performed in all other cases. Statistical analyses
were carried out using GraphPad Prism 6 software version 6.02.
2.2.7 VEP of Non-synonymous SNP Variants
The consequences of the exonic SNPs were predicted using the online Variant Effect
Predictor (VEP) tool on EnsemlGenomes (http://useast.ensembl.org/Tools/VEP). SIFT and
PolyPhen scores were obtained by inputting and running the variant identifiers for Human
(Homo sapiens) on VEP.
2.3 Results
Using the data from the allelic discrimination analysis, genotypic and MAFs were
calculated for the eight SNPs in all groups (Table 4-11). Two SNPs, rs12721655 (MAF 0.8%)
and rs35979566 (MAF 0.8%), were not included in the comparison between blood methadone
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concentration and [methadone]/[EDDP] ratio because the variant allele was not observed in the
methadone-only group.
rs2279344 (MAF =
39.4%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses (All) Only Overdoses
(Male)
37.5%
38.4%
39.3%

WV MethadoneOnly Overdoses
(Female)
25.0%

92.9
98

47.2
45

21.8
18

7.8
11

120.8
120

56.7
59

26.3
32

9.4
8

39.3
35

17.1
17

7.9
6

2.8
1

3.2E-02
0.98
0.69

0.11
0.95
0.91

2.19
0.33
0.30

8.9E-02
0.96
0.26

Table 4: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs227344
*
The expected NCBI MAF is in parentheses beside the db SNP id.
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rs3211371 (MAF =
10.4%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
10.3%
12.4%
13.8%

WV MethadoneOnly Overdoses
(Female)
5.0%

203.1
205

100.6
97

46.7
43

16.1
18

47.2
44

23.1
25

10.7
14

3.7
2

2.7
4

1.3
3

0.6
1

0.2
0

0.82
0.66
0.67

0.79
0.67
0.30

1.3E-02
0.99
0.46

5.5E-02
0.97
0.55

Table 5: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs3211371
*
The expected NCBI MAF is in parentheses beside the db SNP id.
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rs3745274 (MAF =
27%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
22.4%
31.9%
35.1%

WV MethadoneOnly Overdoses
(Female)
37.5%

133.2
156

74.7
58

34.3
25

12.0
6

98.6
76

43.1
53

19.8
24

7.0
13

18.2
18

6.2
13

2.9
8

1.0
1

3.94
0.14
1.1E-02†

3.0E -02
0.99
1.2E-03¶

0.33
0.85
1.8E-03¶

3.0
0.22
1.6E-02‖

Table 6: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs3745274
*
The expected NCBI MAF is in parentheses beside the db SNP id.
Statistically significant in allele frequency as compared to the NCBI Caucasian population. †P <
0.01.
Statistically significant in allele frequency as compared to the control group, ‖P < 0.05, ¶P <
0.005.
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rs4803419 (MAF =
25.1%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
31.1%
24.6%
25.0%

WV MethadoneOnly Overdoses
(Female)
28.9%

142.5
126

57.9
67

27.5
31

9.0
8

95.5
98

52.3
50

24.9
25

8.1
11

16.0
30

11.8
5

5.6
2

1.8
0

2.53
0.28
8.2E-04‡

1.35
0.51
6.6E -02

1.30
0.52
0.25

3.15
0.21
0.23

Table 7: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs4803419
*
The expected NCBI MAF is in parentheses beside the db SNP id.
Statistically significant in allele frequency as compared to the NCBI Caucasian population. ‡P <
0.001.
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rs8192709 (MAF =
3.6%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
5.4%
2.8%
0.9%

WV MethadoneOnly Overdoses
(Female)
2.5%

233.3
227

111.9
118

51.9
57

17.9
19

17.4
21

12.7
7

5.9
1

2.0
1

0.3
3

0.4
0

0.2
0

0.1
0

7.95
1.9E-02§
1.1E-05‡

0.10
0.95
0.20

4.4E-03
1.00
9.3E -02

1.3E-02
0.99
0.72

Table 8: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs8192709
*
The expected NCBI MAF is in parentheses beside the db SNP id.
Statistically significant in allele frequency as compared to the NCBI Caucasian population. ‡P <
0.001.
§
Allele is out of Hardy-Weinberg Equilibrium, P < 0.05.
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rs8192719 (MAF =
27.9%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
23.0%
33.6%
35.8%

WV MethadoneOnly Overdoses
(Female)
39.5%

121.1
144

63.5
48

31.5
23

11.3
6

93.7
71

37.9
46

18.8
22

6.7
11

18.1
18

5.6
13

2.8
8

1.0
2

4.48
0.11
7.3E-03†

0.15
0.93
5.2E-04

0.50
0.77
1.9E-03¶

0.85
0.65
4.5E-02‖

Table 9: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs8192719
*
The expected NCBI MAF is in parentheses beside the db SNP id.
Statistically significant in allele frequency as compared to the NCBI Caucasian population. †P <
0.01.
Statistically significant in allele frequency as compared to the control group, ‖ P < 0.05, ¶ P <
0.005,  P < 0.001.
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rs12721655 (MAF =
0.8%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
0.2%
0.0%
0.0%

WV MethadoneOnly Overdoses
(Female)
0.0%

211.6
214

100.5
101

47.8
48

17.9
18

3.4
1

0.5
0

0.2
0

0.1
0

0
0

0
0

0
0

0
0

1.2E-03
1.00
0.42

ND
ND
0.79

ND
ND
0.89

ND
ND
0.96

Table 10: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs12721655
*
The expected NCBI MAF is in parentheses beside the db SNP id.
ND: minor allele was not detected.
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rs35979566 (MAF =
0.8%)*
Calculated MAF
Homozygous Major
Allele
Expected
Observed
Heterozygotes
Expected
Observed
Homozygous Minor
Allele
Expected
Observed
HWE
2
P-value
Obs vs. Exp Pvalue

Controls Methadone-Only WV MethadoneOverdoses
Only Overdoses
(Male)
1.3%
0.0%
0.0%

WV MethadoneOnly Overdoses
(Female)
0.0%

192.9
191

90.6
93

56.5
58

16.6
17

3.1
5

2.3
0

1.5
0

0.4
0

0
0

0
0

0
0

0
0

0.03
0.98
0.55

ND
ND
0.30

ND
ND
0.47

ND
ND
0.80

Table 11: Minor Allele Frequency, Observed, and Expected Genotypic Frequencies for
rs35979566
*
The expected NCBI MAF is in parentheses beside the db SNP id.
ND: minor allele was not detected.
2.3.1 HWE Analysis
Genotype frequencies within a group were considered to be in HWE if the resulting χ2
value was < 5.99 (corresponding to a P-value > 0.05). SNP rs8192709 in the control group was
out of HWE. The remaining five SNPs were in HWE for the control group. The methadone-only
group was within HWE for all six SNPs.
2.3.2 Comparison of Observed and Expected Genotypic Frequencies
To assess for significant differences between the genotypic frequencies in the control
groups and the NCBI frequencies for the Caucasian population, a χ2 test with two degrees of
freedom was used. We observed that the genotypic frequency of four SNPs (rs3745274,
rs4803419, rs8192709 and rs8192719) was significantly different between our control group and
that of the frequency in the NCBI population. SNPs rs3745274 and rs8192719 in the control
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group had lower than expected MAFs compared to NCBI reported values, 22.4% vs 27.0% and
23.0% vs 27.9%, respectively, while SNPs rs4803419 and rs8192709 observed higher MAFs,
31.1% vs 25.1% and 5.4% vs 3.6%, respectively.
Since many of the control group SNP frequencies were discordant with the NCBI
frequencies, we relied on genotype frequencies of the local control group to identify SNPs that
could contribute to methadone toxicity. SNPs rs3745274 and rs8192719 exhibited a significant
difference in the methadone-only group compared to the control group. For these two SNPs, the
MAF in the methadone-only cases was greater than that of the control group, 31.9% vs 22.4%
and 33.6% vs 23.0%, respectively. When assessing the observed and expected genotypic
frequencies for the male and female groups, the differences in frequencies were preserved in the
both groups. These results are delineated in Table 4.
2.3.3 Analysis of Blood Methadone Concentrations and [Methadone]/[EDDP] Ratios
We tested for associations between SNP genotypes and blood methadone concentrations
using a one-way ANOVA, in conjunction with the Tukey test. For SNP rs3211371, these
analyzes showed a significant increase in the mean blood methadone concentrations (mg/L) in
participants carrying two copies of the variant allele (1.67 ± 0.85) as compared to either the
heterozygote (0.52 ± 0.08) or homozygous ancestral genotype (0.59 ± 0.05). Figure 3 depicts the
mean blood methadone concentrations, with SEM, of each of the genotypes for the SNPs tested.
The metabolic ratio of [methadone]/[EDDP] was significantly lower in heterozygotes carrying
the rs8192709 variant vs the homozygous ancestral genotype (Figure 4). No significant
differences in ratios were observed for the remaining SNPs.
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Figure 3: Comparison for Various CYP2B6 SNPs with SEM of Mean Blood Methadone
Concentrations
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Statistically significant difference, P < 0.01.

M e a n [M e th a d o n e ]/[E D D P ] R a tio

40

30

*

A n ce stra l
20

H eter o zy g o u s
V a r ia n t

10

0
rs2279344

rs3211371

rs3745274

rs4803419

rs8192709

rs8192719

C y to c h r o m e P 4 5 0 2 B 6 S N P

Figure 4: Comparison for Various CYP2B6 SNPs with SEM of Mean [Methadone]/[EDDP]
Ratios
*
Statistically significant difference, P < 0.05.
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2.3.4 Predicted Effects of SNPs on Protein Function
Amino acid substitution (AAS) at the corresponding positions for each of the SNPs were
predicted for their effect on protein function. VEP reports the possible impact of the SNPs using
the SIFT and PolyPhen algorithms. Both algorithms were consistent for rs3211371 and
rs3745274, indicating that the AASs were tolerated and benign, while rs12721655 was predicted
to affect the protein function in a deleterious and possibly damaging manner. Conflicting results
were observed for rs8192709 and rs35979566, where the SIFT algorithm predicted the AASs to
have a deleterious effect on the protein function, while PolyPhen predicted the substitutions to be
benign.
2.4 Discussion
After oral administration, methadone can be detected in the blood within 15 – 45 min,
and peak plasma concentrations can be attained at 2.5 – 4 h. The bioavailability of methadone is
~75%, with a wide range of 36 – 100% (Eap et al., 2002; Lugo et al., 2005; Kapur et al., 2011).
About 86% of methadone binds to α1-acid glycoprotein (AGP), leaving 14% as free plasma
methadone levels (Kapur et al., 2011). The methadone levels in the plasma decrease as the liver
enzymes, CYPs, start to metabolize methadone to the inactive metabolites EDDP and EMDP.
The elimination half-life of methadone ranges from 5 – 130 h, with a mean value of 22 h (Eap et
al., 2002). The pharmacokinetics of methadone encompasses extreme interindividual variability
attributed to factors such as, age, co-administered medications, disease, ethnicity (due to
differing allelic frequency of genetic polymorphisms), gender and weight (Li et al., 2008; Kapur
et al., 2011; Richards-Waugh et al., 2014). In a previous study, Richards-Waugh et al. (2014)
demonstrated that an increasing number of SNPs present in CYP3A4 was associated with an
increasing blood level of methadone.
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Due to the number of factors contributing to the pharmacokinetics of methadone, this
study examined CYP2B6 SNPs in 125 Caucasian individuals who suffered methadone-only
fatalities. Our study eliminated the factors of co-medication and limited it to the allelic frequency
of the Caucasian population in WV and KY. The methadone-only group was a non-random
selection of individuals, chosen for the study based on a particular phenotype (fatalities due to
methadone) of interest in the WV and KY region. In order to accurately determine any
differences in the genotypic frequencies of the SNPs, the methadone-only group was compared
to the regional control group. SNPs rs12721655 and rs35979566 did not exhibit any of the
variant alleles in the methadone group or the control group. This observed genotypic frequency
could be accredited to the low MAF of 0.8%. The study cohort may not have been large enough
to reasonably observe the variant allele. The remaining alleles genotyped had a MAF of at least
2% as reported by the NCBI database. A significant enrichment of the minor alleles of
rs3745274 and rs8192719 was observed in the methadone-only group compared to the control
group, (32.2% vs 22.4% and 33.6% vs 23.0%), for the SNPs, respectively. The data suggests that
these SNP may play a causative role in methadone fatalities. This finding is consistent with the
observation that rs3745274 and rs8192719 are under-represented in a group of individuals with
low (S)-methadone levels (Dobrinas et al., 2013) and suggesting their involvement with
decreased CYP2B6 activity. The significant increase in the number of minor alleles was
preserved in both the male and female cases, indicating that a particular gender does not have a
predisposition to the mutation.
It is unclear if the enrichment of the minor alleles rs3745274 and rs8192719 leads to an
enhancement of the blood level of (S)-methadone in this study, as enantiomer levels of (R)- and
(S)-methadone were not determined at the time of autopsy. While total methadone blood levels
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were not increased by the presence of these SNPs (Figure 3), the ratio of (R)- to (S)-methadone
is unknown. If the ratio of (S)-methadone was increased due to these SNPs, then it is possible
that an increased risk of death from cardiotoxicity would exist.
Parent-to-metabolite ratios are commonly used as an indicator of a recent intake of
certain drugs and are not necessarily indicative of an acute poisoning. In some cases, the
metabolic ratio may provide clues to indicate reduced metabolism of the drug due to a drug
interaction or low metabolic capacity caused by genetics (Druid, Holmgren, Carlsson, & Ahlner,
1999). It was interesting to see a significant decrease (P = 0.04) in the metabolic ratio in
individuals that were heterozygous for rs8192709. These data suggest that rs8192709 may have a
role in metabolizing methadone at a faster rate. This analysis, however, should be interpreted
with caution, as the number of individuals having a variant was minimal (n = 2), and neither
were observed to be homozygous for the variant. A significant increase in the blood methadone
concentration was observed for rs3211371 of homozygous variant alleles when compared to the
ancestral alleles and the heterozygous genotypes (P = 0.002). This finding suggests that
rs3211371 results in the reduced activity of CYP2B6. This finding is contrary to the findings of
Dobrinas et al. (2013). In their study, rs3211371 was over-represented in low-level (S)methadone groups, indicating an increased CYP2B6 activity. This study interprets the findings
based on the various genotypes, whereas Dobrinas et al. (2013) interprets their findings on
MAFs, which may be the reason of the contradictory postulations. Also, Dobrinas et al. (2013)
measured enantiomeric levels of methadone in live MMT patients, while our results are from
autopsy samples. It is also possible that the small sample size of the studies has resulted in these
differences. Additional numbers of cases could be needed to resolve this difference in findings.
A combination of the total number of variant alleles present for all of the SNPs tested for each
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individual in the methadone-only group was determined. The blood methadone concentration
and the [methadone]/[EDDP] ratio was compared to total number of minor alleles present,
ranging from one to five copies of the variant alleles for CYP2B6. The data (not shown) did not
support the assumption that multiple SNPs, rather than a single SNP, on the CYP2B6 gene would
increase the unexpected fatality from methadone.
SNP rs3211371 results in a conversion of arginine to cysteine at amino acid position 487,
while glutamine is converted to histidine at amino acid position 172 as a result of rs3745274.
Tools for annotating functional predictions of coding non-synonymous SNPs, such as SIFT and
PolyPhen, suggested that both of these SNPs are tolerated or benign. On the other hand,
rs8192709 encodes a conversion of arginine to cysteine at amino acid position 22, producing
disagreeing predictions, where SIFT reports the variation to be deleterious, while PolyPhen
predicts the mutation to be benign. CYP2B6 has six substrate recognition sites (SRSs) along its
sequence (Nguyen et al., 2008). SNPs rs3211371, rs3745274 and rs8192709 are not located
within the known SRSs and confer minimal effects on methadone binding; however the SNPs
may affect the hydrophobicity and conformation of the protein, resulting in alteration of the
metabolic rate (Kamal, Lim, Tye, Ismail, & Choong, 2013). Furthermore, rs3745274 has been
associated with increased levels of a hepatic splicing variant lacking exon 4 – 6 and decreased
protein levels, caused by erroneous splicing, leading to decreased metabolism of substrates
(Desta et al., 2007; Hofmann et al., 2008).
Physiologic differences occur between genders, which may affect the outcome of drug
activity (Whitley & Linsdey, 2009). Gender influences the expression of CYPs and transporters,
thus influencing pharmacokinetic parameters (Zanger & Schwab, 2013). Methadone accesses
MOR site through the bloodstream, coming in contact with the plasma protein AGP. AGP is
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capable of binding methadone and rendering it inactive (Behan, Cruickshank, Matthews-Smith,
Bruce, & Smith, 2013). In general, females have a significantly greater binding capacity of AGP
than males, suggesting that females could have a reduced level of free plasma drug levels
(Kishino et al., 2002). In this study, there were no significant differences in the blood methadone
concentration or the [methadone]/[EDDP] ratio between the male and female groups for any of
the SNPs tested (data not shown).
It is important to note that since these cases were obtained from the WV and KY
OCMEs, the medical and prescription history of the deceased individuals was not available. It is
possible that drugs, prescription or natural supplements, or environmental compounds not
detected by the normal toxicology screens could also have contributed to altered methadone
metabolism. Additionally, it is unclear if the ratio of (R)- to (S)-methadone was changed in
association with any CYP2B6 SNPs examined. Research is currently underway to determine the
effects of the exonic SNPs included in this study on the differential metabolism of (R)- and (S)methadone.
2.5 Conclusions
The frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9, c.516G>T, Q172H)
and rs8192719 (21563C>T) were significantly increased in the methadone-only group. SNP
rs3211371 (*5, c.1459C>T, R487C) exhibited a significant increase in the blood methadone
concentration in the homozygous variant genotype, indicating that an individual carrying two
copies of the minor allele for the SNP could have a poor methadone-metabolizer phenotype
leading to an increased risk of fatal methadone intoxication. CYP2B6 only plays a partial role in
the metabolism of (S)-methadone, and therefore the SNPs on this gene are only a part of the
whole story. Richards-Waugh et al. (2014) studied the effects of SNPs on the CYP3A4 gene,
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which metabolizes both the (R)- and (S)- forms of methadone. It is possible that it is a
combination of SNPs on both genes that leads to these unexpected fatalities.
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CHAPTER 3
EFFECTS OF CYTOCHROME P450 2B6 (CYP2B6) SINGLE NUCLEOTIDE
POLYMORPHISMS ON CYP2B6 ACTIVITY: IMPLICATIONS FOR METHADONE
METABOLISM

Abstract
Cytochrome P450 2B6 (CYP2B6) enzyme plays a significant role in the preferential
stereoselective metabolism of (S)-methadone. Concentrations of (S)-methadone above
therapeutic levels have the ability to cause serious, life-threatening, and fatal cardiac side effects.
This toxicity could be due in part to the pharmacogenetics of an individual, which can alter the
pharmacokinetic and pharmacodynamic properties of the drug and contributing to methadone
overdose and death. One of the contributing factors for interindividual variability in
biotransformation is genetic variation within the genes encoding CYP enzymes. Single
nucleotide polymorphisms (SNPs), located within the CYP2B6 gene were previously genotyped
in 125 Caucasians involved in methadone-only overdose deaths to determine if these SNPs have
the potential to play an important role in altering CYP2B6 activity. SNP mutations for
rs2279344, rs3211371, rs3745274, rs8192709, rs12721655, rs35773040, and rs35979566 were
introduced to wild type CYP2B6 plasmid using Agilent QuikChange II Site-Directed
Mutagenesis Kit. Sanger sequencing was performed for all genes to ensure each mutation was
present. Each of the CYP2B6 plasmids were individually expressed in COS-1 cell lines and the
transfected cell lines were selectively grown. CYP2B6 microsomal protein was isolated from the
COS-1 cells. The CYP2B6 activity in microsomal fractions was measured using a Promega
P450-Glo CYP2B6 Assay Kit. Inhibition studies were conducted using clopidogrel to determine
that the activity observed was from CYP2B6. Methadone was used to evaluate competition with
luciferin-2B6 substrate at the active site. The effect of each individual SNP variant resulted in the
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following decreasing order of CYP2B6 activity: rs2279343 > rs3745274 > wild type
(CYP2B6*1), rs3211371 > rs8192709 > rs35773040, rs35979566. Relative to the wild type
CYP2B6, SNPs rs8192709, rs35773040 and rs35979566 yielded 57%, 81%, and 94% decreased
activity, respectively. The inhibition study with methadone indicated that the binding site is the
same as luciferin-2B6 substrate. Therefore, our investigations suggest that rs8192709,
rs35773040, and rs35979566 result in poor metabolizing phenotypes which may be contributing
factors in decreased metabolism of (S)-methadone.
3.1 Introduction
The pharmacogenetics of an individual has the ability to alter the pharmacokinetic and
pharmacodynamics properties of a drug. CYPs are heme-containing enzymes primarily found in
the smooth endoplasmic reticulum of hepatic cells. These enzymes are responsible for catalyzing
the oxidative biotransformation of most drugs. The principal determinant of the pharmacokinetic
properties of xenobiotics is metabolism, thus affecting the resulting pharmacodynamic effects
(Tanka, 1998; Turpeinen, 2006; Zanger & Schwab, 2013).
One of the contributing factors for interindividual variability in biotransformation is
genetic variation within the genes encoding CYP enzymes. SNPs within a CYP gene may alter
the enzymatic properties of the resulting protein, modify the metabolic response to a drug, and
ultimately affect the drug’s therapeutic and adverse effects (Ahmad et al., 2018).
Methadone has a wide-ranging half-life of elimination from 5 – 130 hours and a
bioavailability ranging from 36 – 100%, making it a difficult medication to prescribe due to the
extreme variability in the interindividual pharmacokinetics (Eap et al., 2002). This variation may
be due to SNPs within the CYP genes responsible for the metabolism of methadone (Li et al.,
2008). In most countries, methadone is administered as a racemic mixture of equal amounts of
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(R)- and (S)-methadone. The CYP enzymes stereoselectively metabolize methadone, rendering
distinct enantiomeric pharmacodynamics properties. While analgesic properties are ascribed to
(R)-methadone, concentrations above therapeutic levels lead to respiratory depression by acting
on the MOR controlling respiration in the brainstem (Mitchell et al., 2004; Silverman et al.,
2009; van der Schier et al., 2014). Elevated (S)-methadone levels block the voltage-gated
potassium channel of the hERG gene resulting in potentially fatal cardiotoxicity by prolonging
the QT interval causing torsades de pointes (Eap et al., 2007; Ansermot et al., 2010; Dobrinas et
al., 2013).
CYP2B6 enzyme plays a significant role in the preferential stereoselective metabolism of
(S)-methadone. CYP2B6 has 74 allelic variants and 38 haplotypes, rendering it one of the most
polymorphic genes (Fokkema et al., 2011; Ingelman-Sundberg, 2017; Fokkema & den Dunnen,
2018a). The genetic variants affect catalytic activity, transcriptional regulation, splicing, and
mRNA and protein expression. Therefore, SNPs in CYP2B6, and possibly other CYPs, could be
contributing to the incidence of life-threatening and fatal cardiac side effects of (S)-methadone.
Our laboratory previously genotyped and analyzed numerous CYP2B6 exonic and
intronic SNP variants in 125 Caucasians involved in methadone-only fatalities (Ahmad et al.,
2017). It was found that the frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9,
c.516G>T, Q172H) and rs8192719 (21563C>T), were significantly increased in the methadoneonly group. SNP rs3211371 (*5, c.1459C>T, R487C) exhibited a significant increase in the
blood methadone concentration, and rs8192709 (*2, c.64C>T, R22C) may have a role in
metabolizing methadone at a faster rate. The present work examined the effects of seven exonic
CYP2B6 SNPs, including the exonic SNPs genotyped in the previous study, in the metabolism of
(S)-methadone.
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3.2 Material and Methods
3.2.1 Material
Plasmid EX-NEG-M02, an empty control vector, was used as minus-P450 control.
Plasmid EX-Q0553-M02 with the NCBI accession number: NM_000767.4 sequence, which
cloned the human CYP2B6 gene, was used as a mutagenesis template. All plasmids were
obtained via GeneCopoeia (Rockville, MD). QuickChange II site-directed mutagenesis kit was
purchased from Agilent Technologies (Santa Carla, CA). All primers designed to introduce the
site-directed mutation were obtained from Sigma Life Sciences (The Woodlands, TX). DH5 E.
coli cells, COS-1 cells, and clopidogrel bisulfate were generous gifts from Dr. Emine Koc, Dr.
Jung Han Kim, and Dr. Wei Li, respectively (Marshall University, Huntington, WV, USA).
QIAprep Spin Miniprep and DNeasy® Blood and Tissue kits were purchased from Qiagen
(Germantown, MD). All microbiological and cell culture reagents were purchased from Fisher
Scientific (Hampton, NH) and tissue culture plates were obtained from Midsci (Valley Park,
MO). Pierce BCA protein assay kit was purchased from ThermoFisher Scientific (Waltham,
MA). CYP2B6 (H-110) and goat anti-rabbit IgG-HRP antibodies were obtained from Santa Cruz
Biotechnology (Dallas, TX). Phusion® High-Fidelity PCR Kit was purchased from New England
Biolabs (Ipswich, MA). Microsome Isolation kit was purchased from BioVision (Milpitas, CA).
Corning® Supersomes™ Human CYP2B6 + Oxidoreductase + b5, and Corning® Gentest™
NADPH Regenerating System, Solutions A and B were purchased from Corning (Corning, NY).
P450-Glo™ CYP2B6 Assay and Screening System and beetle luciferin, potassium sulfate were
purchased from Promega (Madison, WI). Racemic methadone (6-dimethylamino-4,4diphenylheptan-3-one) hydrochloride reference standard was obtained from Sigma-Aldrich (St.
Louis, MO).
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3.2.2 CYP2B6 Plasmid Variants
3.2.2.1 Construction of CYP2B6 Plasmid Variants
QuickChange II site-directed mutagenesis kit was used to generate various individual
CYP2B6 constructs from a plasmid carrying the human wild-type CYP2B6 cDNA (CYP2B6*1):
(i) rs2279343 (CYP2B6*4, c.785A>G, K262R); (ii) rs3211371 (CYP2B6*5, c.1459C>T,
R487C); (iii) rs3745274 (CYP2B6*9, c.516G>T, Q172H); (iv) rs8192709 (CYP2B6*2, c.64C>T,
R22C); (v) rs12721655 (CYP2B6*8, c.415A>G, K139E); (vi) rs35773040 (CYP2B6*14,
c.419G>A, R140Q); and (vii) rs35979566 (CYP2B6*15, c.1172T>A, I391N). Following the
manufacturer’s conditions, the reactions were prepared in a final volume of 50 L for each
variant, containing 50 ng wild-type human CYP2B6 plasmid, 125 ng each of the forward and
reverse variant primer, 5 L reaction buffer (10x), 1 L dNTP mix, and ddH2O. Before the start
of each cycle, 1 L of PfuUltra HF DNA polymerase was added to each reaction tube. The
thermal cycling parameters were set for polymerase activation at 95oC for 30 s, followed by 12
cycles of denaturation at 95oC for 30 s, annealing at 55oC for 1 min, and extension at 68oC for 8
min. Following the thermal cycling, the reactions were placed on ice for 2 min. The primers
designed for the plasmid variants are listed in Table 12.
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Target
rs2279343
(CYP2B6*4)
rs3211371
(CYP2B6*5)
rs3745274
(CYP2B6*9)
rs8192709
(CYP2B6*2)
rs12721655
(CYP2B6*8)
rs35773040
(CYP2B6*14)
rs35979566
(CYP2B6*15)
Sanger
Sequencing
Primers
PCR Primers

Forward Primer (5’  3’)
CAGCGCCCCCAGGGACCTCATC

Reverse Primer (5’  3’)
GATGAGGTCCCTGGGGGCGCTG

CCCAACATACCAGATCTGCTTCCTGCCCCG

CGGGGCAGGAAGCAGATCTGGTATGTTGGG

CCACCTTCCTCTTCCATTCCATTACCGCCAAC GTTGGCGGTAATGGAATGGAAGAGGAAGGTGG
GCTACTCCTGGTTCAGTGCCACCCTAACACC

GGTGTTAGGGTGGCACTGAACCAGGAGTAGC

GGATGGGAGAGCGGAGTGTGGAG

CTCCACACTCCGCTCTCCCATCC

GGATGGGAAAGCAGAGTGTGGAGGAGC

GCTCCTCCACACTCTGCTTTCCCATCC

GAAGTATTTCTCAACCTGAGCACTGCTCTCC

GGAGAGCAGTGCTCAGGTTGAGAAATACTTC

CAGCCTCCGGACTCTAGC
CACTATGAGGGACTTCGGGA
CGTCCTCCTCTTCCTTGCACTCC
CAAGGACCTCATCGACACCTAC
ATAGAAGACACCGGGACCGA*
CAGCCTCCGGACTCTAGC†
CAAGGACCTCATCGACACCTAC‡

TAATACGACTCACTATAGGG
GATGGAGCAGATGATGTT
AGCAGTTTTCCCAGTCACGA*
GATGGAGCAGATGATGTT†
TAATACGACTCACTATAGGG‡

Table 12: Forward and Reverse Primers for Construction of CYP2B6 Plasmid Variants, Sanger Sequencing, and PCR
Amplification
*
Annealing temperature calculated from www.neb.com/TmCalculator is 65oC
†
Annealing temperature calculated from www.neb.com/TmCalculator is 56oC; 1.5 L of DMSO was added to the PCR reaction
‡
Annealing temperature calculated from www.neb.com/TmCalculator is 63oC; 1.5 L of DMSO was added to the PCR reaction
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3.2.2.2 Transformation and Amplification of CYP2B6 Plasmid Variant
Competent DH5 E. coli cells were incubated on ice for 30 min with 5 ng of the resulting
PCR variants products. The cells were heat shocked at 42oC for 45 s and then placed back on ice
to recover for 2 min. The transformed cells were allowed to grow overnight at 37oC on agar
plates with 1x ampicillin for selection. An isolated colony from the agar plate, for each variant,
was propagated in NZY+ broth with 1x ampicillin at 37oC overnight with shaking. Transformed
DH5 E. coli cells were collected for plasmid extraction following the manufacturer’s protocol
for the QIAprep Spin Miniprep Kit. The purified plasmids were quantitated by absorbance
spectrophotometry on a NanoDrop 1000. The CYP2B6 variant plasmids were then given to the
Marshall University Genomics Core Facility to conduct Sanger sequencing to verify the variants
were present. Two forward primers and a reverse primer were used for sequencing all plasmids
(listed in Table 12).
3.2.3 Transfection of COS-1 Cells
COS-1 cells were used for stable expression of the CYP2B6 plasmid variants. For each
individual variant, three wells in a 6-well tissue culture plate were seeded with 100,000 COS-1
cells in DMEM + 10% FBS. A lipid-DNA complex was formed using 300 ng of plasmid and 3
L of Lipofectamine 2000 diluted to 200 L with DMEM. The cells were washed with cold PBS
and 800 L of DMEM + 10% FBS was added to each plate along with 200 L of their respective
lipid-DNA complex (variant plasmid complexes for CYP2B6 expression or an empty control
vector for negative control). The cells were grown in a humidified incubator at 37oC with 5%
CO2. The media was changed after 24 h to selective media (DMEM + 10% FBS + 1% P/S +
1mg/mL Geneticin) and incubated for an additional 24 h. The cells were recovered 48 h posttransfection from the three wells and diluted to one cell per well into 96-well tissue culture plates
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to construct single clones. The remaining cells where stored under cryogenic conditions. Once
the wells were about 80% confluent, the cells were gradually expanded to 48-well, 24-well, 12well, 6-well, 60-mm, and 100-mm tissue culture plates, consecutively.
3.2.4 Determination of Protein Expression by Western Blot
The expression of CYP2B6 variant proteins in COS-1 single clone cell lines were
assessed using Western blot analysis. Protein was extracted from cells grown to 80-90%
confluency in a 60-mm tissue culture plate using 100 L RIPA buffer with 1x protease inhibitor.
The protein concentration for each sample was determined using the Pierce BCA protein assay
kit, following the manufacturer’s protocol. An aliquot of 10 g of protein of each sample was
denatured by boiling for 5 min. The proteins were separated on a 10% polyacrylamide gel for 1 h
at 130V. The gel was then transferred to a nitrocellulose membrane for 1 h at 0.35A. The
successful transfer and protein loading was verified using Ponceau S stain. The membrane was
then blocked for nonspecific antibody binding using a 5% w/v non-fat milk/TBST solution (10
mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) for 1 h. A rabbit polyclonal CYP2B6 (H110) primary antibody (1:1000) was diluted in 5% non-fat milk/TBST and applied on the
membrane for incubation at 4oC overnight with continual rocking. The membrane was then
washed three times with TBST for 7 min before the goat anti-rabbit HRP-linked secondary
antibody (1:5000 dilution in 5% non-fat milk/TBST) was added for 1 h incubation. The
membrane was again washed with TBST for 7 min, three times. The proteins were detected with
the application of ECL and exposure to X-ray film. GAPDH was used as a loading control for all
of the Western blots to confirm equal protein loading.
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3.2.5 Verification of Plasmid Variant in Protein Expression
Once protein expression was determined via Western blotting, the CYP2B6 gene was
again sequenced to verify the protein was expressing the SNP variant. Each cell line was grown
to 80-90% confluency in a 100-mm tissue culture plate. The DNA was purified from the cells
following the manufacturer’s protocol for the DNeasy® Blood and Tissue Kit. The extracted
DNA was quantitated using the NanoDrop 1000. Phusion® High-Fidelity PCR Kit was used to
amplify the CYP2B6 gene in a PCR reaction. Following the manufacturer’s conditions, the
reactions were prepared in a final volume of 50 L for each sample containing 150 ng of the
purified template DNA, 10 L of 5x Phusion HF, 2.5 L each of 10 M forward and reverse
primer, 1 L of 10 mM dNTPs, nuclease-free water to volume, and lastly 0.25 L Phusion DNA
polymerase. The thermocycling conditions were set on three stages: stage one for initial
denaturation at 98oC for 30 s, followed by stage two for 30 cycles of denaturation at 98oC for 10
s, annealing at 51o, 56o, or 65oC for 30 s, and extension at 72oC for 26 s, and stage three for a
final extension at 72oC for 5 min. Following the cycling conditions, the samples were held at
4oC. The primers designed for the PCR are listed in Table 12.
Positive PCR amplification was determined through Southern blot analysis on the PCR
products using a 1% agarose gel with ethidium bromide at a final concentration of 0.5 g/mL.
The PCR products were then given to the Marshall University Genomics Core Facility to
conduct Sanger sequencing to verify the variants were present. The sequencing primers used are
listed in Table 12. DNA BASER Sequence Assembler v.4.36.0 was used to align the sequence
reads to a reference sequence to form a single continuous contig for each sample. The resulting
contig was subsequently aligned to the reference plasmid sequence using the multiple sequence
alignment by CLUSTALW (https://www.genome.jp/tools-bin/clustalw).
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3.2.6 Isolation and Quantitation of Microsomal Protein
After the confirmation of the presence of the CYP2B6 SNP variants in the stable
constructs of COS-1 cells, twenty 100-mm tissue culture plates of each cell line were grown to
yield approximately 2 x 107 cells. The cells were collected for isolation of microsomal fractions
by differential centrifugation following the manufacturer’s protocol for BioVision’s Microsome
Isolation Kit. In short, all steps were performed on ice. The cells were homogenized via
sonication and then centrifuged at 10,000 x g for 15 min at 4oC. The supernatant was then
centrifuged at 25,000 x g for 20 min at 4oC. The resulting pellet was resuspended in storage
buffer and stored at -80oC. The protein concentration for each microsomal extraction was
determined using the Pierce BCA protein assay kit. An aliquot of 20 g of microsomal protein
for each sample was used for Western blot analysis as previously described. For each gel, 0.05,
0.1, 0.15, and 0.2 pmol of Corning® SupersomeTM Human CYP2B6 was loaded as standards to
produce a standard curve. Densitometry was measured with ImageJ PC-based software (National
Institute of Health) to extrapolate the concentration of CYP2B6 in each COS-1 microsomal
extract from the standard curve.
3.2.7 P450-GloTM Assay
3.2.7.1 Measuring CYP2B6 SNP activity
The P450-GloTM CYP2B6 assay was performed in accordance to the manufacturer’s
protocol in white opaque polystyrene nontreated flat-bottom 96-well plates. In short, 0.1 pmol of
each CYP2B6 SNP variant microsomal protein were incubated with 25 L of 2X substrate
solution (final concentration of 3 M luciferin-2B6) for 10 min at 37oC. CYP2B6 reactions were
initiated with the addition of 25 L 2X NADPH regeneration system and incubated for an
additional 10 min at 37oC. An addition of 50 L detection reagent was added to cease the
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reaction and shaken on an orbital shaker at a frequency of 282 rpm for 10 s and incubated for 20
min at room temperature in the dark. Luminescence signals were measured using a Synergy
HTX multi-mode microplate reader. The CYP2B6 activity was normalized to activity detected
for the empty vector microsomal fractions (minus-P450 control). All reactions were performed in
triplicate.
3.2.7.2 Inhibition of CYP2B6 activity
CYP2B6 was selectively inhibited with a final concentration of 0.5 M and 1.0 M
clopidogrel to ensure the activity observed was from the CYP2B6 enzyme. Similarly, 0.1 pmol
of CYP2B6*1 microsomal protein was incubated with 12.5 L of 4X substrate solution (final
concentration of 3 M luciferin-2B6) and 12.5 L of the appropriate clopidogrel stock solution
for 10 min at 37oC. The reaction was initiated with the addition of 25 L 2X NADPH
regeneration system and incubated for an additional 10 min at 37oC. The reaction was terminated
and luminescent signal was initiated with the addition of 50 L detection reagent. The plate was
shaken on an orbital shaker at a frequency of 282 rpm for 10 s and incubated for 20 min at room
temperature in the dark. Luminescence signals were measured on a microplate reader as above.
The CYP2B6 activity was normalized to activity detected for the untreated control at each
incubation time point. All reactions were performed in triplicate.
Various concentrations of racemic methadone (3, 6, 12, 60, 120, and 240 M) was also
used to test for inhibition. The reactions were carried out and luminescence signals were
measured and normalized in the same manner as the inhibition with clopidogrel. All reactions
were performed in triplicate.
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3.2.8 Statistical Analysis
Statistical analyses were carried out using GraphPad Prism software version 7.02. The
CYP2B6 SNP activity was compared to wild type CYP2B6 activity using one-way ANOVA
with Dunnett’s multiple comparison test. P-values < 0.05 were considered to be statistically
significant.
3.3 Results and Discussion
In order to test the effects of missense variants on human CYP2B6 enzymatic activity, we
created a wild type CYP2B6 expression vector in plasmid EX-Q0553-M02 and a series of
variant CYP2B6 expression vectors. We then expressed the resulting enzymes by stable
transfection in COS-1 cells. The COS-1 cell line was selected because CYPs are not innately
expressed by these cells. COS-1 cells also have ample oxidoreductase and cytochrome b5 to
support the CYP2B6 activity (Gonzalez & Korzekwa, 1995). The variant constructs included the
following missense substitutions: (1) rs2279343 (CYP2B6*4, c.785A>G, K262R), (2) rs3211371
(CYP2B6*5, c.1459C>T, R487C), (3) rs3745274 (CYP2B6*9, c.516G>T, Q172H), (4)
rs8192709 (CYP2B6*2, c.64C>T, R22C), (5) rs12721655 (CYP2B6*8, c.415A>G, K139E), (6)
rs35773040 (CYP2B6*14, c.419G>A, R140Q), and (7) rs35979566 (CYP2B6*15, c.1172T>A,
I391N) (Appendix B). We successfully transfected the wild type construct and all variant
construct with the exception of the SNP rs12721655 variant plasmid. This observation may stem
from lethal effects of the variant enzyme and is consistent to the predicted SIFT and PolyPhen
algorithms of rs12721655 having a deleterious and possibly damaging protein function (Ahmad
et al., 2017). As a result, no further studies were conducted on the SNP.
Expression of the wild type and variant proteins was confirmed by Western blot analysis
on whole cell extracts with CYP2B6 (H-110) antibody (Figure 5); a 55kDa band was not
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detected in the empty vector transfectant. After verification of protein expression, the presence of
the CYP2B6 genetic variants in COS-1cells was confirmed by amplification and sequencing of
the CYP2B6 gene (Appendix B).

Figure 5: Western Blot Analysis of CYP2B6 Variant Protein Expression from Whole Cell
Lysates
The activity of the wild type and variant enzymes was measured in COS-1 microsomal
extracts using the Promega P450-Glo CYP2B6 Assay Kit. In this assay, CYP2B6 enzymes
metabolized a luminogenic luciferin-2B6 substrate to produce d-luciferin that generates light
proportional to the CYP2B6 activity. Since SNP rs8192709 produced a lower than expected
microsomal extract, 0.086pmol of the variant proteins were used to compare SNP activity. The
activity of the CYP2B6 protein variants was rs2279343 > rs3745274 > wild type (CYP2B6*1),
rs3211371 > rs8192709 > rs35773040, rs35979566 (Figure 6). Similar results were seen using
0.1 pmol microsomal protein (data not shown). Compared to the wild type CYP2B6, SNPs
rs2279343 and rs3745274 resulted in a 90% and 55% increase in CYP2B6 activity, respectively
(P < 0.0001). In contrast, SNPs rs8192709, rs35773040, and rs35979566 yielded decreased
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CYP2B6 activity by, 57%, 81%, and 94%, respectively (P < 0.0001). SNP rs3211371 had
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activity comparable to the wild type CYP2B6 enzyme (Figure 6).

SN P

Figure 6: Effect of CYP2B6 SNPs on CYP2B6 Enzyme Activity.
Results are the mean with SEM of three P450-Glo reactions. 0.086 pmoles of 2B6 enzyme were
loaded into assay.
****
Statistically significant difference with respect to wild type CYP2B6, P < 0.0001.

Clopidogrel is a selective inhibitor of CYP2B6, inactivating the cytochrome activity
primarily through the destruction of the heme subunit. Clopidogrel is metabolically
biotransformed to the active metabolite 2-oxo-clopidogrel by CYP2B6. Covalent modification of
Cys475 of CYP2B6 by 2-oxo-clopidogrel may also lead to the loss of the catalytic activity of
CYP2B6 (Zhang, Amunugama, Ney, Cooper, & Hollenberg, 2011). Using clopidogrel as an
inhibition control confirmed that the induced activity observed was from the CYP2B6 enzyme.
Addition of 0.5 M clopidogrel and 1 M clopidogrel to wild type CYP2B6 microsomal extracts
resulted in reduction of CYP2B6 activity by 62% and 86%, respectively (P < 0.0001) (Figure 7).
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The inhibitory concentration at which the CYP2B6 enzyme activity is reduced by 50% (IC50)
was determined to be 0.393 M using the online source AAT Bioquest IC50 Calculator (Quest
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Graph™ IC50 Calculator, 2018).

Figure 7: Wild Type CYP2B6 Enzyme Activity Inhibited by 0.5 M and 1 M of
Clopidogrel
Results are the mean with SEM of three reactions. Statistically significant difference compared
to untreated wild type CYP2B6 enzyme, ****P < 0.0001.
Racemic methadone was used as a test compound to determine the effect on the wild type
CYP2B6 enzyme. Inhibition by clopidogrel determined the capacity of the system to detect
inhibition by racemic methadone. Significant inhibition was not seen at racemic methadone
concentrations of 3 M, 6 M, and 12 M (data not shown). However, concentrations at 60 M,
120 M, and 240 M, resulted in an inhibition of the wild type CYP2B6 enzyme with a
significant decrease in activity by 24%, 34%, and 46%, respectively (P < 0.005, P < 0.0005, and
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P < 0.0001, respectively) (Figure 8). The IC50 value was calculated to be 304 M of racemic
methadone, over 100 times the luciferin-2B6 concentration in the assays, indicating methadone is
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a weak competitive inhibitor for the substrate luciferin-2B6.

Figure 8: Wild Type CYP2B6 Enzyme Activity Inhibited by 60 M, 120 M, and 240 M
of Racemic Methadone
Results are the mean with SEM of three reactions. Statistically significant difference compared
to untreated wild type CYP2B6 enzyme, **P < 0.005, ***P < 0.0005, ****P < 0.0001.
SNP rs2279343 (K262R) also resulted in an increase in activity as compared to the wild
type CYP2B6. In the CYP2B family, variant R262 is involved in a hydrogen-bonding network in
the G and H helices, along with their associated loops, which includes H252, T255, D263, and
D266. The ancestral K262 of CYP2B6 disrupts this hydrogen-bonding network, which may
affect the G and I helices and alter the active site (Gay, Roberts, & Halpert, 2010). SNP
rs2279343 reverts the lysine in position 262 to the CYP2B conserved arginine residue, which
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may increase the plasticity of CYP2B6 to adopt different confirmations when binding to
different substrates, thus resulting in an increase in the observed activity.
In previous studies, the frequency of the exonic SNP rs3745274 was observed to be
significantly increased in 125 Caucasian individuals who suffered fatalities due to methadone, in
the WV and KY regions (Ahmad et al., 2017), indicating SNPs rs3745274 may be linked to
methadone toxicity overdosing. However, the activity of CYP2B6 SNP rs3745274 (Q172H)
when compared to the wild type CYP2B6 yielded an increase in CYP2B6 activity (P < 0.0001),
indicating the SNP results in an ultra-rapid metabolizer phenotype. These results were not in
agreement to the findings by Gadel et al. (2015), who found that the in vitro intrinsic clearance
of methadone to its principal metabolite, EDDP, was significantly less in the mutant than the
wild type CYP2B6 from insect cells co-expressed with oxidoreductase and cytochrome b5.
Similarly, clinical genetic association studies of concentration-to-dosage ratios and methadone
plasma concentrations were consistent with diminished methadone N-demethylation in the
presence of the rs3745274 SNP (Wang et al., 2011; Levran et al., 2013).
One of the most common CYP2B6 variant alleles is CYP2B6*6, a haplotype harboring
both the rs2279343 (K262R) and rs3745274 (Q172H) non-synonymous coding SNPs.
Individually, both of these SNPs increased the activity of CYP2B6 enzymes in our studies.
Numerous in vitro and clinical studies reported CYP2B6*6 genotype has been linked with an
increase in methadone plasma levels, decreased methadone N-demethylation, and decreased
methadone clearance (Gadel et al., 2015; Crettol et al., 2005; Crettol et al., 2006; Kharasch &
Stubbert, 2013; Kharasch et al., 2015; Kringen et al., 2017). The CYP2B6*6 allele has been
associated with reduced protein levels, which may be correlated to rs3745274 involved in the
erroneous hepatic splicing of exons 4, 5 and 6 yielding a truncated protein and concurrently
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altering the catalytic activity of the enzyme. In silico analysis of the splice sites suggest an
exonic splicing enhancer may be modulated by rs3745274 in exon 4. These observations were
from the expression and analysis of minigene constructs created and expressed in COS-1 and
Huh7 cell lines by Hofmann et al. containing all nine exons of CYP2B6, introns 2, 5, and 7, and
the 5’ and 3’ parts of introns 3 and 6. The minigenes lacked introns 1, 4, and 8 and parts of intron
3 and 6 (Hofmann et al., 2008). However, linkage disequilibrium (LD) analysis in an Israeli
population supported the inclusion of the intronic SNP rs8192719 (intron 8, g.21563C>T) in the
CYP2B6*6 haplotype (Levran et al., 2013). Although an LD analysis was not performed in our
previous study, all subjects identified with the rs3745274 SNP also had the rs8192719 SNP
(unpublished data). It is possible that decreased activity of CYP2B6*6 may be causal from the
intronic SNP, affecting splice-dependent quantitative and qualitative expression of CYP2B6,
controlling the efficacy and toxicity of methadone.
The CYP2B6 activity of SNP rs3211371 was comparable to that of the wild type
CYP2B6. In comparison to various clinical and decedent studies, these findings were not
consistent. Individuals homozygous for SNP rs3211371 of methadone-only deceased cohort by
Ahmad et al. (2017), had a significant increase in blood methadone concentrations, suggesting a
PM phenotype. In another study, SNP rs3211371 was over-represented in individuals with low
(S)-methadone levels, indicating an increase in CYP2B6 activity (Dobrinas et al., 2013). While,
the IV and oral methadone plasma concentrations of SNP rs3211371 homozygote subjects
resembled those seen in the cohort homozygous for the wild type CYP2B6 (Kharasch et al.,
2015).
Reduced CYP2B6 activity was observed with SNP rs8192709, causing a nonsynonymous amino acid change in position 22 from a large, positively charged arginine to a
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medium, nonpolar nucleophilic cysteine. Protein folding may be interfered by cross bridges
formed by cysteine residues, increasing the rigidity of the protein. SNP rs35773040 causes an
amino acid change from a positively charged arginine to a polar, uncharged glutamine at position
140. This mutation is located at the end of the C-D loop (Nguyen et al., 2008), which may
disrupt interactions with the D helix of CYP2B6, resulting in conformational modifications.
Replacement of the hydrophobic Ile391 with a less bulky polar uncharged residue (asparagine),
due to SNP rs35979566, diminished the CYP2B6 activity. This effect may be related to the
position of this residue directly between the 1-3 sheet and the K’ helix (Nguyen et al., 2008).
CYP2B6 is only one enzyme involved in the metabolism of (S)-methadone. Cytochromes
2D6 and 2C18 also preferentially metabolize (S)-methadone, while CYP3A4 demonstrates no
stereoselectivity, metabolizing both (R)- and (S)-methadone (Ahmad et al., 2018). The
contradictory results seen in this and other studies with clinical data could be in part due to a
combination of these CYPs and are not only that of CYP2B6 alone.
3.4 Conclusions
In summary, metabolically competent cell systems were generated by stable transfection
with individual CYP2B6 variant plasmids in COS-1 cells. The effect of introducing one exonic
SNP resulted in the following decreasing order of CYP2B6 activity: rs2279343 > rs3745274 >
wild type (CYP2B6*1), rs3211371 > rs8192709 > rs35773040, rs35979566. SNPs rs8192709,
rs35773040 and rs35979566 yielded 57%, 81%, and 94% decreased activity relative to wild type
CYP2B6, respectively. Methadone binds to the same active site and competes with the luciferin2B6 substrate used to measure CYP2B6 activity. Therefore, our results suggest that these three
SNPs could contribute to PM phenotypes and may influence the pharmacokinetics and
pharmacodynamics of (S)-methadone.
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CHAPTER 4
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS
It is interesting to observe the history and trends of methadone use unfold over the last 20
years; once a miracle drug, methadone is now a killer cure. In the mid-1990s, methadone was
increasingly prescribed as a treatment for chronic nonmalignant pain because of its long duration
of analgesic action and relatively low cost (Paulozzi, Mack, & Jones, 2012). In 2003, West
Virginia was one of the first states to start reporting increases in fatal overdoses associated with
methadone (Lipman, 2008). By 2004, the methadone mortality rate in West Virginia increased
25-fold compared to 1999, while Kentucky showed the fourth largest increase at 15-fold
(Fingerhut, 2006). The rate of methadone overdoses peaked in 2006, plateaued in 2007, and then
declined 6.5%, on average, in each subsequent year (Jones et al., 2016; Faul, Bohm, &
Alexander, 2017).
The main determinant of methadone mortality rates parallel the amount of methadone
distributed for pain relief through prescriptions (Paulozzi et al., 2012). In 2006, the FDA issued a
public health advisory for respiratory depression and cardiac arrhythmias leading to
unintentional overdose deaths related to methadone used for pain, which was quickly followed
with issuance of black box warnings by drug manufacturers (Christie, 2011). At the request of
the Drug Enforcement Agency (DEA), manufacturers voluntarily limited the distribution of the
40 mg methadone formulation to MMT programs and hospitals at the beginning of 2008, since
this dosage was not approved for treatment of pain. The steps taken by the FDA and DEA to
improve the safety of methadone usage may have caused the resulting decline in methadone
related mortality rate in consistence with the decrease in the national distribution of methadone
(Paulozzi et al., 2012). However, the overdose death rate in people 55 – 64 years of age
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continued to rise through 2014 and remains a drug that disproportionately contributes to fatal
overdoses among opioid pain relievers (Paulozzi et al., 2012; Jones et al., 2016).
Methadone mortality rate can partially be attributed to the genetic makeup of an
individual. SNPs in regions of the genome that express drug metabolizing enzymes, CYPs, may
have consequences that lead to decreased metabolism of methadone leading to unintentional
overdoses. The CYP2B6 enzyme is one of the predominant metabolizers of methadone, and a
major determinant of stereoselective metabolism of (S)-methadone (Chang et al., 2011).
Studying and understanding the pharmacogenetic factors in methadone metabolism can help
mediate the proper dosing regimen for an individual for safe and effective therapeutic success in
pain relief. Several pharmacogenetic studies on CYP2B6 have been previously conducted
involving patients in MMT programs (Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007;
Wang et al., 2011; Dobrinas et al., 2013; Kharasch & Stubbert, 2013; Levran et al., 2013;
Kharasch et al., 2015; Kringen et al., 2017). However, these studies had small sample sizes
(Kharasch & Stubbert, 2013), included multidrug cases rather than single-drug methadone cases
(Eap et al., 2007; Wang et al., 2011), or consisted of subject groups of mixed populations
(Crettol et al., 2005; Crettol et al., 2006; Dobrinas et al., 2013; Levran et al., 2013; Kharasch et
al., 2015). The work presented in this dissertation is from the largest methadone-only fatalities
from a single population cohort. It is a unique pharmacogenetic study designed to gain
knowledge in the prevalence and function of SNPs in CYP2B6.
The current study was designed to extract the genomic DNA of 125 Caucasian subjects
from the Appalachian region (WV and KY) involved in methadone-only fatalities from blood
stain cards, along with a control group consisting of 225 deceased Caucasian individuals from
WV who screened negative for central nervous system drugs. Eight key exonic and intronic SNP
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variants present in the Caucasian population were genotyped to test for enrichment in the
subjects. The analyses performed in this study were aimed to provide insight into the association
of CYP2B6 SNPs in individuals who succumb to methadone intoxication in the methadone-only
cases. Many of the control group SNP frequencies were significantly different from the MAF
reported for the general Caucasian population in the NCBI dbSNP database (Tables 6 – 9). These
differences indicated that the population in the Appalachia region has evolved, and as such, we
relied on genotypic frequencies of the local control group to identify SNPs that could contribute
to methadone toxicity. The frequencies of two SNPs on the CYP2B6 gene, rs3745274 (*9,
c.516G>T, Q172H) and rs8192719 (21563C>T) were significantly increased in the methadoneonly group compared to the control group (Tables 6 and 9). Associations were also analyzed
between SNP genotypes and blood methadone concentrations. SNP rs3211371 exhibited a
significant increase in the blood methadone concentration in the homozygous variant genotype as
compared to either the heterozygous or homozygous ancestral genotype (Figure 3). This study
suggested that these three SNPs may be associated as contributory factors to increased
methadone mortality rates.
In addition to the pharmacogenetic association study, the effect of each individual exonic
SNP on the activity of the CYP2B6 enzyme was determined. This current study was conducted
by generating metabolically competent cell systems by stably transfecting individual CYP2B6
exonic variant plasmids in COS-1 cell lines. The effect of each exonic SNP on enzyme activity
was measured using a luminogenic CYP assay and compared to the wild type CYP2B6 enzyme.
This study showed that the genetic variants of CYP2B6 influences the enzymatic activity in the
following decreasing order: rs2279343 > rs3745274 > wild type (CYP2B6*1), rs3211371 >
rs8192709 > rs35773040, rs35979566. SNPs rs8192709, rs35773040, and rs35979566 yielded
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57%, 81%, and 94% decreased activity relative to wild type CYP2B6, respectively. To further
explore the effect of these SNPs on the metabolism of methadone, various methadone
concentrations were added to the assay to competitively inhibit CYP2B6 activity. The data
indicated that methadone also binds to the CYP2B6 active site and competes with the
luminogenic substrate used to measure the activity. Therefore, our investigations suggest that
these three SNPs may contribute to CYP2B6 PM phenotypes and may influence the
pharmacokinetics and pharmacodynamics of (S)-methadone leading to unanticipated fatalities.
Since the time of the genotyping study, a TaqMan® SNP Genotyping kit for SNP
rs35773040 (C__34816082_30) has become available. A custom designed assay for
rs2279343 (AHBJ12M) can now also be obtained through ThermoFisher Scientific
(Bloom et al., 2013). These kits should be used to genotype the methadone-only and
control cases. With this additional information, the CYP2B6*6 haplotype, which is made
up by SNPs rs2279343 and rs3745274, can be identified in these individuals. Statistical
analysis, conducted as described in Chapter 2, could reveal more SNPs that may be
associated with methadone overdoses in the WV and KY populations.
The purpose of this study was to determine the role of CYP2B6 SNPs in the unexpected
death due to methadone overdoses. While it has unveiled SNPs enriched in those deceased
individuals from the heart of the Appalachia region and SNPs that reduce the enzymatic activity
of CYP2B6, there are several questions left unanswered. The data amongst the association and
functionality studies are not complimentary. SNP rs3745274 was enhanced in methadone-only
cases, however the SNP yielded an increase in CYP2B6 activity. Similarly, SNP rs3211371 was
correlated with a significant increase in the blood methadone concentration, yet the effect of
CYP2B6 activity was comparable to the wild type. While rs8192709 was associated with an
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increase in methadone metabolism, the CYP2B6 activity was significantly decreased with the
presence of this SNP. We determined the effect of individual SNPs on the activity of the
CYP2B6 enzyme; however, the deceased individuals expressed multiple SNPs in their genetic
profile for methadone metabolizing CYPs. The combined effect of SNPs on multiple CYPs may
be the contributory factor to the discrepancies observed between the two studies. In order to
understand the complexity of the effects of CYP2B6 SNPs on methadone pharmacokinetics and
pharmacodynamics, further functionality testing should be conducted with combinations of
SNPs. For example, a plasmid constructed to contain the common haplotype CYP2B6*6, would
be useful since clinical evidence suggests this genotype influences methadone disposition
(Crettol et al., 2005; Crettol et al., 2006; Eap et al., 2007; Wang et al., 2011). Any number of
CYP2B6 SNP combinations would impart a greater understanding in the effects of the SNPs in
CYP2B6 activity, be it a compound effect with multiple PM SNPs or a null effect with an
extensive metabolizer SNP in combination with a PM SNP.
The CYP2B6 enzyme is only involved partially in the metabolism of (S)-methadone, and
therefore, the SNPs on this gene are only a fraction of the whole story. Previous studies
conducted by our laboratory determined the association of SNPs on the CYP3A4 gene, which
metabolizes both the (R)- and (S)- forms of methadone. It was found that SNPs rs2242480 and
rs2740574 were enriched within the methadone-only group (Richards-Waugh et al., 2014).
Studies on the effect of these CYP3A4 SNPs should be conducted as outlined in Chapter 3. It is
possible that it is a combination of SNPs on both the CYP2B6 and CYP3A4 genes leads to
unintentional methadone overdoses. This additional research will help elucidate the role of the
different CYPs and their polymorphisms in methadone pharmacokinetics and thus the
therapeutic outcome.

76

REFERENCES
Ahmad, T., Sabet, S., Primerano, D. A., Richards-Waugh, L. L., & Rankin, G. O. (2017, May).
Tell-tale SNPs: The role of CYP2B6 in methadone fatalities. Journal of Analytical
Toxicology, 41(4), 325-333. doi:10.1093/jat/bkw135
Ahmad, T., Valentovic, M. A., & Rankin, G. O. (2018, July). Effects of cytochrome P450 single
nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Biochemical Pharmacology, 153, 196-204. doi:10.1016/j.bcp.2018.02.020
Anderson, I. B., & Kearney, T. E. (2000, January). Use of Methadone. Western Journal of
Medicine, 172, 43-46. doi:10.1136/ewjm.172.1.43
Anggård, E., Gunne, L.-M., Holmstrand, J., McMahon, R. E., Sandberg, C.-G., & Sullivan, H. R.
(1975). Disposition of methadone in methadone maintenance. Clinical Pharmacology &
Therapeutics, 17(3), 258-266. doi:http://dx.doi.org/10.1002/cpt1975173258
Ansermot, N., Albayrak, Ö., Schläpfer, J., Crettol, S., Croquette-Krokar, M., Bourquin, M., . . .
Eap, C. B. (2010, March 22). Substitution of (R,S)-Methadone by (R)-Methadone Impact
on QTc Interval. Archives of internal medicine, 170(6), 529-536.
doi:10.1001/archinternmed.2010.26
Bart, G. (2012, July). Maintenance Medication for Opiate Addiction: The Foundation of
Recovery. Journal of Addictive Diseases, 31(3), 207-225.
doi:10.1080/10550887.2012.694598
Behan, J. L., Cruickshank, Y. E., Matthews-Smith, G., Bruce, M., & Smith, K. D. (2013). The
glycosylation of AGP and its associations with the binding to methadone. BioMed
Research International, 2013(108902). doi:10.1155/2013/108902
Bloom, A. J., Martinez, M., Chen, L.-S., Bierut, L. J., Murphy, S. E., & Goate, A. (2013,
November 15). CYP2B6 Non-Coding Variation Associated with Smoking Cessation Is
Also Associated with Differences in Allelic Expression, Splicing, and Nicotine
Metabolism Independent of Common Amino-Acid Changes. PLoS One, 8(11), e79700.
doi:10.1371/journal.pone.0079700
Boulton, D. W., Arnaud, P., & DeVane, C. L. (2001). Pharmacokinetics and pharmacodynamics
of methadone enantiomers after a single oral dose of racemate. Clinical Pharmacology
and Therapeutics, 70(1), 48-57. doi:10.1067/mcp.2001.116793
Carlquist, J. F., Moody, D. E., Knight, S., Johnson, E. G., Fang, W. B., Huntinghouse, J. A., . . .
Anderson, J. L. (2015). A Possible Mechanistic Link Between the CYP2C19 Genotype,
the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP),
and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study. Molecular
Diagnosis and Therapy, 19(2), 131-138. doi:10.1007/s40291-015-0137-4

77

CDC. (2012, July 3). Vital Signs: Prescription Painkiller Overdoses. Retrieved August 2016,
from Centers for Disease Control and Prevention:
https://www.cdc.gov/vitalsigns/MethadoneOverdoses/index.html
Chang, Y., Fang, W. B., Lin, S.-N., & Moody, D. E. (2011, January). Stereo-Selective
Metabolism of Methadone by Human Liver Microsomes and cDNA-Expressed
Cytochrome P450s: A Reconciliation. Basic & Clinical Pharmacology & Toxicology,
108(1), 55-62. doi:10.1111/j.1742-7843.2010.00628.x
Christie, J. M. (2011, Spring-Summer). Opioid Prescribing: Methadone Risk Mitigation. The
Anesthesia Patient Safety Foundation Newsletter, 26(1), pp. 1, 13-15. Retrieved April 6,
2019, from https://www.apsf.org/wpcontent/uploads/newsletters/2011/spring/pdf/APSF201106.pdf
Coller, J. K., Joergensen, C., Foster, D. J., James, H., Gillis, D., Christrup, L., & Somogyi, A. A.
(2007). Lack of influence of CYP2D6 genotype on the clearance of ( R ) - , ( S ) - and
racemic-methadone. International journal of clinical pharmacology and therapeutics,
45(7), 410-417. doi:10.5414/CPP45410
Crettol, S., Déglon, J.‐J., Besson, J., Croquette‐Krokar, M., Gothuey, I., Hämmig, R., . . . Eap, C.
B. (2005). Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9
genotypes, and response to treatment. Clinical Pharmacology and Therapeutics, 78(6),
593-604. doi:10.1016/j.clpt.2005.08.011
Crettol, S., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Hämmig, R., Gothuey, I., . . . Eap, C.
B. (2006). ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on
methadone plasma levels and response to treatment. Clinical Pharmacology and
Therapeutics, 80(6), 668-681. doi:10.1016/j.clpt.2006.09.012
Csajka, C., Crettol, S., Guidi, M., & Eap, C. B. (2016). Population Genetic-Based
Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in
Opioid-Dependent Patients. Clinical Pharmacokinetics, 55(12), 1521-1533.
doi:10.1007/s40262-016-0415-2
Daly, A. K. (2004, December). Pharmacogenetics of the cytochromes P450. Current Topics in
Medicinal Chemistry, 4(16), 1733-1744. doi:10.2174/1568026043387070
Daly, A. K. (2016, July 27). CYP2 Family. The Biomedical & Life Sciences Collection.
Newcastle, Tyne and Wear, England: Henry Stewart Talks. Retrieved from
https://hstalks.com/t/685/
De Fazio, S., Gallelli, L., De Siena, A., De Sarro, G., & Scordo, M. G. (2008). Role of CYP3A5
in Abnormal Clearance of Methadone Salvatore. Annals of Pharmacotherapy, 42(6), 893897. doi:10.1345/aph.1K539
DePriest, A. Z., Puet, B. L., Holt, A. C., Roberts, A., & Cone, E. J. (2015, July). Metabolism and
Disposition of Prescription Opioids: A Review. Forensic Science Review, 27(2), 115-145.
Retrieved from
78

https://www.researchgate.net/profile/Edward_Cone/publication/280583461_Metabolism_
and_Disposition_of_Prescription_Opioids_A_Review/links/55bf5fb708aed621de12fd90/
Metabolism-and-Disposition-of-Prescription-Opioids-A-Review.pdf
Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., . . . Zanger, U. M. (2007,
June). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
PHARMACOGENOMICS, 8(6), 547-558. doi:10.2217/14622416.8.6.547
Dinis-Oliveira, R. J. (2016). Metabolomics of methadone: clinical and forensic toxicological
implications and variability of dose response. Drug Metabolism Reviews, 48(4), 568-576.
doi:10.1080/03602532.2016.1192642
Dobrinas, M., Crettol, S., Oneda, B., Lahyani, R., Rotger, M., Choong, E., . . . Eap, C. B. (2013,
February). Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma
levels A CYP2B6 gene resequencing study. Pharmacogenetics and Genomics, 23(2), 8493. doi:10.1097/FPC.0b013e32835cb2e2
Dole, V. P., & Nyswander, M. (1965). A medical treatment for diacetylmorphine (heroin)
addiction: A clinical trial with methadone hydrochloride. JAMA, 193(8), 646-650.
doi:10.1001/jama.1965.03090080008002
Drucker, E., Lurie, P., Wodakt, A., & Alcabes, P. (1998). Measuring harm reduction: the effects
of needle and syringe exchange programs and methadone maintenance on the ecology of
HIV. AIDS, 12 (Suppl A), S217-S230.
Druid, H., Holmgren, P., Carlsson, B., & Ahlner, J. (1999). Cytochrome P450 2D6 (CYP2D6)
genotyping on postmortem blood as a supplementary tool for interpretation of forensic
toxicological results. Forensic Science International, 99(1), 25-34. doi:10.1016/S03790738(98)00169-8
Eap, C. B., Broly, F., Mino, A., Haemmig, R., Déglon, J. J., Uehlinger, C., . . . Baumann, P.
(2001). Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Journal of clinical psychopharmacology, 21(2), 229-234. doi:10.1097/00004714200104000-00016
Eap, C. B., Buclin, T., & Baumann, P. (2002, December). Interindividual variability of the
clinical pharmacokinetics of methadone: implications for the treatment of opioid
dependence. Clinical Pharmacokinetics, 41(14), 1153-1193. doi:10.2165/00003088200241140-00003
Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer , J., Grilo, L. S., Déglon, J.-J., . . . Abriel, H.
(2007, May). Stereoselective block of hERG channel by (S)-methadone and QT interval
prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics,
81(5), 719-728. doi:10.1038/sj.clpt.6100120
Faul, M., Bohm, M., & Alexander, C. (2017, March 31). Methadone Prescribing and Overdose
and the Association with Medicaid Preferred Drug List Policies — United States, 2007–
79

2014. Morbidity and Mortality Weekly Report (MMWR), 66(12), pp. 320-323.
doi:http://dx.doi.org/10.15585/mmwr.mm6612a2
Ferrari, A., Coccia, C. P., Bertolini, A., & Sternieri, E. (2004). Methadone - Metabolism,
pharmacokinetics and interactions. Pharmacological Research, 50(6), 551-559.
doi:10.1016/j.phrs.2004.05.002
Fingerhut, L. A. (2006, December). Increases in Methadone-Related Deaths: 1999-2004.
National Center for Health Statistics. Retrieved April 3, 2019, from
https://www.cdc.gov/nchs/data/hestat/methadone1999-04/methadone1999-04.htm
Fokkema, I. F., & den Dunnen, J. T. (2015a, October 24). CYP2C18 (cytochrome P450, family 2,
subfamily C, polypeptide 18). Retrieved March 29, 2019, from LOVD v.3.0 - Leiden
Open Variation Database Online gene-centered collection and display of DNA variants:
https://www.lovd.nl/CYP2C18
Fokkema, I. F., & den Dunnen, J. T. (2015b, May 22). CYP2C8 (cytochrome P450, family 2,
subfamily C, polypeptide 8). Retrieved March 29, 2019, from LOVD v.3.0 - Leiden Open
Variation Database Online gene-centered collection and display of DNA variants:
http://www.LOVD.nl/CYP2C8
Fokkema, I. F., & den Dunnen, J. T. (2017, August 4). CYP1A2 (cytochrome P450, family 1,
subfamily A, polypeptide 2). Retrieved March 29, 2019, from LOVD v.3.0 - Leiden Open
Variation Database Online gene-centered collection and display of DNA variants:
https://www.LOVD.nl/CYP1A2
Fokkema, I. F., & den Dunnen, J. T. (2018a, September 14). CYP2B6 (cytochrome P450, family
2, subfamily B, polypeptide 6). Retrieved March 29, 2019, from LOVD v.3.0 - Leiden
Open Variation Database Online gene-centered collection and display of DNA variants:
http://www.LOVD.nl/CYP2B6
Fokkema, I. F., & den Dunnen, J. T. (2018b, December 2018). CYP2C19 (cytochrome P450,
family 2, subfamily C, polypeptide 19). Retrieved March 29, 2019, from LOVD v.3.0 Leiden Open Variation Database Online gene-centered collection and display of DNA
variants: http://www.LOVD.nl/CYP2C19
Fokkema, I. F., & den Dunnen, J. T. (2019, February 26). CYP2C9 (cytochrome P450, family 2,
subfamily C, polypeptide 9. Retrieved March 29, 2019, from LOVD v.3.0 - Leiden Open
Variation Database Online gene-centered collection and display of DNA variants:
http://www.LOVD.nl/CYP2C9
Fokkema, I. F., Taschne, P. E., Schaafsma, G. C., CellI, J., Laros, J. F., & den Dunnen, T.
(2011). LOVD v.2.0: The next generation in gene variant databases. Human Mutation,
32(5), 557-563. doi:10.1002/humu.21438
Fonseca, F., de la Torre, R., Díaz, L., Pastor, A., Cuyàs, E., Pizarro, N., . . . Torrens, M. (2011,
May). Contribution of cytochrome P450 and ABCB1 genetic variability on methadone
80

pharmacokinetics, dose requirements, and response. PLoS ONE, 6(5), e19527.
doi:10.1371/journal.pone.0019527
Foster, D. J., Somogyi, A. A., & Bochner, F. (1999). Methadone N-demethylation in human liver
microsomes: Lack of stereoselectivity and involvement of CYP3A4. British Journal of
Clinical Pharmacology, 47(4), 403-412. doi:10.1046/j.1365-2125.1999.00921.x
Fredheim, O. M., Moksnes, K., Borchgrevink, P. C., Kaasa, S., & Dale, O. (2009, August).
Clinical pharmacology of methadone for pain. Acta Anaesthesiologica Scandinavica,
52(7), 879-889. doi:10.1111/j.1399-6576.2008.01597.x
Gadel, S., Crafford, A., Regina, K., & Kharach, E. (2013). Methadone N-demethylation by the
common CYP2B6 allelic variant CYP2B6.6. Drug Metabolism and Disposition, 41(4),
709-713. doi:10.1124/dmd.112.050625
Gadel, S., Friedel, C., & Kharasch, E. D. (2015). Differences in methadone metabolism by
CYP2B6 variants. Drug Metabolism and Disposition, 43(7), 994-1001.
doi:10.1124/dmd.115.064352
Gaertner, J., Voltz, R., & Ostgathe, C. (2008, August). Methadone: A Closer Look at the
Controversy. Journal of pain and symptom management, 36(2), e4-7.
doi:10.1016/j.jpainsymman.2008.04.007
Gay, S. C., Roberts, A. G., & Halpert, J. R. (2010). Structural Features of Cytochromes P450 and
Ligands that Affect Drug Metabolism as Revealed by X-ray Crystallography and NMR.
Future Medicinal Chemistry, 2(9), 1451-1468. doi:10.4155/fmc.10.229
Gonzalez, F. J., & Korzekwa, K. R. (1995). Cytochromes P450 Expression Systems. Annual
Review of Pharmacology and Toxicology, 35(1), 369-390.
doi:10.1146/annurev.pa.35.040195.002101
Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeffeler, E., Schwab, M., &
Zanger, U. M. (2008). Aberrant splicing caused by single nucleotide polymorphism
c.516G>T , a marker of CYP2B6*6, is responsible for decreased expression and activity
of CYP2B6 in Liver. The Journal of Pharmacology and Experimental Therapeutics,
325(1), 284-292. doi:10.1124/jpet.107.133306
Holzinger, E. R., Grady, B., Ritchie, M. D., Ribaudo, H. J., Acosta, E. P., Morse, G. D., . . .
Haas, D. W. (2012). Genome-wide association study of plasma efavirenz
pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6
variants. Pharmacogenetics and Genomics, 22(12), 858-867.
doi:10.1097/FPC.0b013e32835a450b
Honda, M., Muroi, Y., Tamaki, Y., Saigusa, D., Suzuki, N., Tomioka, Y., . . . Hiratsuka, M.
(2011). Functional characterization of CYP2B6 allelic variants in demethylation of
antimalarial artemether. Drug Metabolism and Disposition, 39(10), 1860-1865.
doi:10.1124/dmd.111.040352
81

Ingelman-Sundberg, M. (2017, February 9). The Human Cytochrome P450 (CYP) Allele
Nomenclature Database Alle Nomenclature for Cytochrome P450 enzymes. (M.
Ingelman-Sundberg , A. K. Daly, & D. W. Nebert, Eds.) Retrieved March 15, 2019, from
https://www.pharmvar.org/htdocs/archive/index_original.htm
Institute of Medicine. (1995). Federal Regulation of Methadone Treatment. (R. A. Rettig & A.
Yarmolinsky, Eds.) Washington, DC: The National Academies Press. doi:10.17226/4899
Iribarne, C., Berthou, F., Baird, S., Dréano, Y., Picart, D., Bail, J. P., . . . Ménez, J. F. (1996).
Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in
human liver microsomes. Chemical Research in Toxicology, 9(2), 365-373.
doi:10.1021/tx950116m
Jackman, R. P., Purvis, J. M., & Mallett, B. S. (2008, November 15). Chronic nonmalignant pain
in primary care. American Family Physician, 78(10), 1155-1162. Retrieved from
https://pdfs.semanticscholar.org/a0a8/8ebcc6d35229924ab9e5e6aa22947e0d59d2.pdf
Johansson, I., & Ingelman-Sundberg, M. (2008). CNVs of human genes and their implication in
pharmacogenetics. Cytogenetic and Genome Research, 123, 195-204.
doi:10.1159/000184709
Jones, C. M., Baldwin, G. T., Manocchio, T., White, J. O., & Mack, K. A. (2016, July 8). Trends
in Methadone Distribution for Pain Treatment, Methadone Diversion, and Overdose
Deaths — United States, 2002–2014. Morbidity and Mortality Weekly Report (MMWR),
65(26), pp. 667-671. doi:http://dx.doi.org/10.15585/mmwr.mm6526a2
Joseph, H., Stancliff, S., & Langrod, J. (2000, October/November). Methadone maintenance
treatment (MMT): A Review of Historical and Clinical Issues. The Mount Sinai Journal
of Medicine, 67(5 & 6), 347-364.
Jurica, J., & Sulcova, A. (2012). Determination of Cytochrome P450 Metabolic Activity Using
Selective Markers. In J. Paxton (Ed.), Topics on Drug Metabolism (pp. 191-220). InTech.
doi:10.5772/30236
Kahan, M., Srivastava, A., Wilson, L., Mailis-Gagnon, A., & Midmer, D. (2006, September 10).
Opioids for managing chronic non-malignant pain: safe and effective prescribing.
Canadian Family Physician, 52(9), 1091-1096. Retrieved from
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1783736/
Kamal, N. N., Lim, T. S., Tye, G. J., Ismail, R., & Choong, Y. S. (2013). The effect of CYP2B6,
CYP2D6, and CYP3A4 alleles on methadone binding: A molecular docking study.
Journal of Chemistry, 2013(249642). doi:10.1155/2013/249642
Kapur, B. M., Hutson, J. R., Chibber, T., Luk, A., & Selby, P. (2011). Methadone: a review of
drug-drug and pathophysiological interactions. Critical Reviews in Clinical Laboratory
Sciences, 48(4), 171-195. doi:10.3109/10408363.2011.620601

82

Kharasch, E. D., & Stubbert, K. (2013). Role of cytochrome P4502B6 in methadone metabolism
and clearance. The Journal of Clinical Pharmacology, 53(3), 305-313.
doi:10.1002/jcph.1
Kharasch, E. D., Regina, K. J., Blood, J., & Friedel, C. (2015). Methadone Pharmacogenetics:
CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.
Anesthesiology, 123(5), 1142-1153. doi:10.1097/ALN.0000000000000867
Kim, J.-H., Cheong, H. S., Park, B. L., Kim, L. H., Shin, H. J., Na, H. S., . . . Shin, H. D. (2015).
Direct sequencing and comprehensive screening of genetic polymorphisms on CYP2
family genes (CYP2A6, CYP2B6, CYP2C8, and CYP2E1) in five ethnic populations.
Archives of pharmacal research, 38(1), 115-128. doi:10.1007/s12272-014-0348-y
Kishino, S., Nomura, A., Itoh, S., Nakagawa, T., Takekuma, Y., Sugawara, M., . . . Miyazaki, K.
(2002). Age- and gender-related differences in carbohydrate concentrations of α1-acid
glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
European Journal of Clinical Pharmacology, 58(9), 621-628. doi:10.1007/s00228-0020530-x
Kreek, M. J., Levran, O., Reed, B., Schlussman, S. D., Zhou, Y., & Butelman, E. R. (2012,
October). Opiate addiction and cocaine addiction: Underlying molecular neurobiology
and genetics. The Journal of Clinical Investigation, 122(10), 3387-3391.
doi:10.1172/JCI60390
Kringen, M. K., Chalabianloo, F., Bernard, J.-P., Bramness, J. G., Molden, E., & Høiseth, G.
(2017, October). The combined effect of CYP2B6 genotype and other candidate genes on
a steady-state serum concentration of methadone in opioid maintenance treatment.
Therapeutic Drug Monitoring, 39(5), 550-555. doi:10.1097/FTD.0000000000000437
Kristensen, K., Blemmer, T., Angelo, H. R., Christrup, L. L., Drenck, N. E., Rasmussen, S. N., &
Sjøgren, P. (1996). Stereoselective pharmacokinetics of methadone in chronic pain
patients. Therapeutic Drug Monitoring, 18(3), 221-227. doi:10.1097/00007691199606000-00001
Kristensen, K., Christensen, C. B., & Christrup, L. L. (1995, February). The mu1, mu2, delta,
kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life
Sciences, 56(2), PL45-PL50. doi:10.1016/0024-3205(94)00937-6
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2012). Genetic contribution to
variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 54(10),
256-569. doi:10.1016/j.addr.2012.09.017
Lang, T., Klein, K., Richter, T., Zibat, A., Kerb, R., Eichelbaum, M., . . . Zanger, U. M. (2004).
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians:
demonstration of phenotypic null alleles. The Journal of pharmacology and experimental
therapeutics, 311(1), 34-43. doi:10.1124/jpet.104.068973

83

Langrod, J., Lowinson, J., & Ruiz, P. (1981). Methadone treatment and physical complaints: a
clinical analysis. The International Journal of the Addictions, 16(5), 947-952.
doi:10.3109/10826088109038903
Lee, H.-Y., Li, J.-H., Sheu, Y.-L., Tang, H.-P., Chang, W.-C., Tang, T.-C., . . . Liu, R.-H. (2013).
Moving toward Personalized Medicine in the Methadone Maintenance Treatment
Program: A Pilot Study on the Evaluation of Treatment Responses in Taiwan. BioMed
Research International, 2013(741403). doi:10.1155/2013/741403
Lehotay, D. C., George, S., Etter, M. L., Graybiel, K., Eichhorst, J. C., Fern, B., . . . Kapur, B.
(2005). Free and bound enantiomers of methadone and its metabolite, EDDP in
methadone maintenance treatment: Relationship to dosage? Clinical Biochemistry, 38,
1088-1094. doi:10.1016/j.clinbiochem.2005.09.009
Lemke, T. L., Williams, D. A., Roche, V. F., & Zito, S. W. (2012). Central Analgesics. In T. L.
Lemke, & D. A. Williams (Eds.), Foye's principles of medicinal chemistry: Seventh
edition (7th ed., pp. 686-687). Wolters Kluwer Health Adis (ESP).
Leshner, A. I. (1997, August). Drug Abuse and Addiction Treatment Research. Archives Of
General Psychiatry, 54(8), 691-694. doi:10.1001/archpsyc.1997.01830200015002
Levran, O., Peles, E., Hamon, S., Rand, M., Adelson, M., & Kreek, M. J. (2013, July). CYP2B6
SNPs are associated with methadone dose required for effective treatment of opioid
addiction. Addiction Biology, 18(4), 709-716. doi:10.1111/j.1369-1600.2011.00349.x.
Li, Y., Kantelip, J.-P., Gerritsen-van Schieveen, P., & Davani, S. (2008). Interindividual
variability of methadone response: impact of genetic polymorphism. Molecular diagnosis
& therapy, 12(2), 109-124. doi:10.1007/BF03256276
Lipman, J. (2008). The Methadone Poisoning Epidemic. The Forensic Examiner (Summer
2008), pp. 38-46. Retrieved April 3, 2019, from
https://www.deadiversion.usdoj.gov/mtgs/methadone_alert/forensic_examiner_17_38_20
08.pdf#search=methadone
Lisberg, P., & Scheinmann, F. (2013). Is it Time to Consider Use of Levo-methadone (R-(-)Methadone) to Replace Racemic Methadone? Journal of Developing Drugs, 2(2).
doi:10.4172/2329-6631.1000109
Lugo, R. A., Satterfield, K. L., & Kern, S. E. (2005). Pharmacokinetics of Methadone. Journal of
Pain & Palliative Care Pharmacotherapy, 19(4), 13-24. doi:10.1080/J354v19n04_05
Mallinckrodt Pharmaceuticals, Inc. (2016, December). Methadose™ Oral Concentrate
(methadone hydrochloride oral concentrate USP) and Methadose™ Sugar-Free Oral
Concentrate (methadone hydrochloride oral concentrate USP) dye-free, sugar-free,
unflavored. METHADOSE label. Hazelwood, MO, USA. Retrieved November 3, 2017,
from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017116s029lbl.pdf

84

McCance-Katz, E. F. (2011, April). (R)-methadone versus racemic methadone: what is best for
patient care? Addiction, 106(4), 687-688. doi:10.1111/j.1360-0443.2011.03374.x
McDonough, M. (2013, June). Opioid treatment of opioid addiction. Australian Prescriber,
36(3), 83-87. doi:10.18773/austprescr.2013.033
McGraw, J., & Waller, D. (2012). Cytochrome P450 variations in different ethnic populations.
Expert Opinion on Drug Metabolism & Toxicology, 8(3), 371-382.
doi:10.1517/17425255.2012.657626
Mitchell, T. B., Dyer, K. R., Newcombe, D., Salter, A., Somogyi, A. A., Bochner, F., & White, J.
M. (2004). Subjective and physiological responses among racemic- methadone
maintenance patients in relation to relative (S)- vs. (R)-methadone exposure. British
Journal of Clinical Pharmacology, 58(6), 609-617. doi:10.1111/j.13652125.2004.02221.x British
Moody, D. E., Alburges, M. E., Parker, R. J., Collins, J. M., & Strong, J. M. (1997, December).
The Involvement of Cytochrome P450 3A4 in theN-Demethylation ofl-α-Acetylmethadol
(LAAM), norLAAM, and Methadone. Drug Metabolism and Disposition, 25(12), 13471353.
Nanovskaya, T. N., Deshmukh, S. V., Nekhayeva, I. A., Zharikova, O. L., Hankins, G. D., &
Ahmed, M. S. (2004). Methadone metabolism by human placenta. Biochemical
Pharmacology, 68, 583-591. doi:10.1016/j.bcp.2004.04.011
NCBI Resource Coordinators. (2016, January 4). Database resources of the National Center for
Biotechnology Information. Nucleic Acids Research, 44(D1), D7-D19.
doi:https://doi.org/10.1093/nar/gkv1290
Nguyen, T.-A., Tychopoulos, M., Bichat, F., Zimmermann, C., Flinois, J.-P., Diry, M., . . . de
Waziers, I. (2008). Improvement of cyclophosphamide activation by CYP2B6 mutants:
from in silico to ex vivo. Molecular pharmacology, 73(4), 1122-1133.
doi:10.1124/mol.107.042861
Oda, Y., & Kharasch, E. D. (2001, September 1). Metabolism of Methadone and levo-alphaAcetylmethadol (LAAM) by Human Intestinal Cytochrome P450 3A4 (CYP3A4):
Potential Contribution of Intestinal Metabolism to Presystemic Clearance and
Bioactivation. The Journal of Pharmacology and Experimental Therapeutics, 298(3),
1021-1032.
Paulozzi, L. J., Mack, K. A., & Jones, C. M. (2012, July 6). Vital Signs: Risk for Overdose from
Methadone Used for Pain Relief — United States, 1999–2010. Morbidity and Mortality
Weekly Report (MMWR), 61(26), pp. 493-497. Retrieved April 3, 2019, from Morbidity
and Mortality Weekly Report (MMWR):
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6126a5.htm?s_cid=mm6126a5_w
Peles, E., Linzy, S., Kreek, M. J., & Adelson, M. (2013, November/December). Prospective
study of QTc changes among former opiate addicts since admission to methadone
85

maintenance treatment: benzodiazepine risk. Journal of addiction medicine, 7(6), 428434. doi:10.1097/ADM.0b013e3182a8a4f2
Quest Graph™ IC50 Calculator. (2018). (AAT Bioquest, Inc.) Retrieved March 20, 2019, from
https://www.aatbio.com/tools/ic50-calculator
Reisine, T., Law, S. F., Blake, A., & Tallent, M. (1996). Molecular mechanisms of opiate
receptor coupling to G proteins and effector systems. Annals of the New York Academy of
Sciences, 780, 168-175. doi:10.1111/j.1749-6632.1996.tb15121.x
Richards-Waugh, L. L., Primerano, D. A., Dementieva, Y., Kraner, J. C., & Rankin, G. O.
(2014). Fatal Methadone Toxicity: Potential Role of CYP3A4 Genetic Polymorphism.
Journal of Analytical Toxicology, 38(8), 541-547. doi:10.1093/jat/bku091
Risch, N. J. (2000, June 15). Searching for genetic determinants in the new millennium. Nature,
405(6788), 847-856. doi:10.1038/35015718
Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-involved
overdose deaths: United States, 2010–2015. US Department of Health and Human
Services. Atlanta: Centers for Disease Control and Prevention.
doi:10.15585/mmwr.mm655051e1
Sadee, W., Wang, D., Papp, A. C., Pinsonneault, J. K., Smith, R. M., Moyer, R. A., & Johnson,
A. D. (2011, February 2). Pharmacogenomics of the RNA world: structural RNA
polymorphisms in drug therapy. Clinical pharmacology and therapeutics, 89(3), 355365. doi:10.1038/clpt.2010.314
Silverman, D. A., Nettleton, R. T., Spencer, K. B., Wallisch, M., & Olsen, G. D. (2009,
December 31). S-Methadone augments R-methadone induced respiratory depression in
the neonatal guinea pig. Respiratory Physiology & Neurobiology, 169(3), 252-261.
doi:10.1016/j.resp.2009.09.001
Smith, H. S. (2009, July). Opioid Metabolism. Mayo Clinic Proceedings, 84(7), 613-624.
doi:10.4065/84.7.613
Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., . . . Dawson,
E. P. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically
diverse population. Pharmacogenomics, 5(7), 895-931. doi:10.1517/14622416.5.7.895
Somogyi, A. A., Barratt, D. T., Ali, R. L., & Coller, J. K. (2014). Pharmacogenomics of
methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027.
doi:10.2217/pgs.14.56
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009, August). Opioid dependence treatment:
options in pharmacotherapy. Expert Opinion in Pharmacotherapy, 10(11), 1727-1740.
doi:10.1517/14656560903037168

86

Sullivan, H. R., & Due, S. L. (1973). Urinary metabolites of dl-methadone in maintenance
subjects. Journal of Medicinal Chemistry, 16(8), 909-913. doi:10.1021/jm00266a009
Tamási, V., & Falus, A. (2012). Genetic and Epigenetic Factors Affecting Cytochrome P450
Phenotype and Their Clinical Relevance. In J. Paxton (Ed.), Topics on Drug Metabolism
(pp. 87-110). InTech. doi:10.5772/36451
Tanka, E. (1998). Clinically important pharmacokinetic drug-drug interactions: role of
cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23(6), 403416. doi:10.1046/j.1365-2710.1998.00086.x
Taylor, W. F., Finkel, A. G., Robertson, K. R., Anderson, A. C., Toomey, T. C., Abashian, S. A.,
& Mann, J. D. (2000). Methadone in the Treatment of Chronic Nonmalignant Pain: A 2Year Follow-up. Pain Medicine, 1(3), 254-259. doi:10.1046/j.1526-4637.2000.00027.x
Toombs, J. D., & Kral, L. A. (2005, April 1). Methadone treatment for pain states. American
Family Physician, 71(7), 1353-1358. Retrieved from
https://www.aafp.org/afp/2005/0401/p1353.html
Trescot, A. M., & Faynboym, S. (2014). A review of the role of genetic testing in pain medicine.
Pain Physician, 17(5), 425-445.
Turpeinen, M. (2006). Cytochrome P450 enzymes—in vitro, in vivo, and in silico studies. (K.
Nurkkala, Ed.) Oulu, Finland: Oulu University Press. Retrieved from
http://jultika.oulu.fi/files/isbn9514282205.pdf
van der Schier, R., Roozekrans, M., van Velzen, M., Dahan, A., & Niesters, M. (2014,
September 4). Opioid-induced respiratory depression: reversal by non-opioid drugs.
F1000Prime Reports. doi:10.12703/P6-79
Wang, H., & Tompkins, L. M. (2008). CYP2B6: New Insights into a Historically Overlooked
Cytochrome P450 Isozyme. Current Drug Metabolism, 9(7), 598-610.
doi:10.2174/138920008785821710
Wang, J.-S., & DeVane, C. L. (2003). Involvement of CYP3A4, CYP2C8, and CYP2D6 in the
metabolism of (R)- and (S)-methadone in vitro. Drug Metabolism and Disposition, 31(6),
742-747. doi:10.1124/dmd.31.6.742
Wang, L.-L., Li, Y., & Zhou, S.-F. (2009). A Bioinformatics Approach for the Phenotype
Prediction of Nonsynonymous Single Nucleotide Polymorphisms in Human Cytochromes
P450. The American Society for Pharmacology and Experimental Therapeutics, 37(5),
977-991. doi:10.1124/dmd.108.026047
Wang, S.-C., Ho, I.-K., Tsou, H.-H., Liu, S.-W., Hsiao, C.-F., Chen, C.-H., . . . Liu, Y.-L. (2013).
Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects
and treatment dose in a methadone maintenance cohort. Omics: a journal of integrative
biology, 17(10), 519-526. doi:10.1089/omi.2012.0068

87

Wang, S.-C., Ho, I.-K., Tsou, H.-H., Tian, J.-N., Hsiao, C.-F., Chen, C.-H., . . . Liu, Y.-L.
(2011). CYP2B6 polymorphisms influence the plasma concentration and clearance of the
methadone S-enantiomer. Journal of clinical psychopharmacology, 31(4), 463-469.
doi:10.1097/JCP.0b013e318222b5dd
Watanabe, T., Sakuyama, K., Sasaki, T., Ishii, Y., Ishikawa, M., Hirasawa, N., & Hiratsuka, M.
(2010, July). Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2CYP2B6.28, except CYP2B6.22). Pharmacogenetics and Genomics, 20(7), 459-462.
doi:10.1097/FPC.0b013e32833bba0e
Whitley, H. P., & Linsdey, W. (2009). Sex-based differences in drug activity. American Family
Physician, 80(11), 1254-1258.
Yang, H.-C., Chu, S.-K., Huang, C.-L., Kuo, H.-W., Wang, S.-C., Liu, S.-W., . . . Liu, Y.-L.
(2016). Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment
Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L
Associated with Plasma Concentrations of Methadone R- and S-enantiomers in HeroinDependent Patients. PLoS Genetics, 12(3), e1005910. doi:10.1371/journal.pgen.1005910
Zanger, U. M., & Klein, K. (2013, March). Pharmacogenetics of cytochrome P450 2B6
(CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Frontiers
in Genetics, 4(24). doi:10.3389/fgene.2013.00024
Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism:
Regulation of gene expression, enzyme activities, and impact of genetic variation.
Pharmacology and Therapeutics, 138(1), 103-141.
doi:10.1016/j.pharmthera.2012.12.007
Zhang, H., Amunugama, H., Ney, S., Cooper, N., & Hollenberg, P. F. (2011). Mechanism-based
inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both
covalent modification of cysteinyl residue 475 and loss of heme. Molecular
Pharmacology, 80(5), 839-847. doi:10.1124/mol.111.073783
Zhou, S.-F. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance:
Part II. Clinical pharmacokinetics, 48(12), 761-804. doi:10.2165/11318070-00000000000000
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009, December). Polymorphism of human cytochrome
P450 enzymes and its clinical impact. Drug Metabolism Reviews, 41(2), 89-295.
doi:10.1080/03602530902843483
Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2017, October). Worldwide Distribution
of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects.
Clinical Pharmacology & Therapeutics, 102(4), 688-700. doi:10.1002/cpt.690

88

APPENDIX A: INSTITUTIONAL REVIEW BOARD APPROVAL
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APPENDIX B: MULTIPLE SEQUENCE ALIGNMENT OF CYP2B6 SNP PLASMID VARIANTS1 TO NCBI REFERENCE
SEQUENCE PRE- AND POST-TRANSFECTION2 OF COS-1 CELLS

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (CYP2B6*4)
rs3211371 (CYP2B6*5)

ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50
ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50
ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50
ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50

rs8192709 (CYP2B6*2)
rs12721655 (*8, c.415A>G)

ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50
ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50

rs35979566 (CYP2B6*15)

ATGGAACTCA GCGTCCTCCT CTTCCTTGCA CTCCTCACAG GACTCTTGCT 50

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100
ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100
ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100
ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

ACTCCTGGTT CAGTGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100
ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100

rs35979566 (*15, c.1172T>A)

ACTCCTGGTT CAGCGCCACC CTAACACCCA TGACCGCCTC CCACCAGGGC 100

1

Single nucleotide polymorphisms (SNPs) are highlighted in turquoise.

2

Transfection of COS-1 cells with SNP rs12721655 variant plasmid was lethal and resulted in cell death. Therefore, Sanger sequencing on this SNP was

performed only on the plasmid pre-transfection.
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150
CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150
CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150
CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150
CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150

rs35979566 (*15, c.1172T>A)

CCCGCCCTCT GCCCCTTTTG GGAAACCTTC TGCAGATGGA TAGAAGAGGC 150

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200
CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200
CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200
CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200
CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200

rs35979566 (*15, c.1172T>A)

CTACTCAAAT CCTTTCTGAG GTTCCGAGAG AAATATGGGG ACGTCTTCAC 200

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250
GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250
GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250
GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250
GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250

rs35979566 (*15, c.1172T>A)

GGTACACCTG GGACCGAGGC CCGTGGTCAT GCTGTGTGGA GTAGAGGCCA 250
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300
TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300
TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300
TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300
TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300

rs35979566 (*15, c.1172T>A)

TACGGGAGGC CCTTGTGGAC AAGGCTGAGG CCTTCTCTGG CCGGGGAAAA 300

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350
ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350
ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350
ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350
ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350

rs35979566 (*15, c.1172T>A)

ATCGCCATGG TCGACCCATT CTTCCGGGGA TATGGTGTGA TCTTTGCCAA 350

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400
TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400
TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400
TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400
TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400

rs35979566 (*15, c.1172T>A)

TGGAAACCGC TGGAAGGTGC TTCGGCGATT CTCTGTGACC ACTATGAGGG 400

92

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450
ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450
ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450
ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450
ACTTCGGGAT GGGAGAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450

rs35979566 (*15, c.1172T>A)

ACTTCGGGAT GGGAAAGCGG AGTGTGGAGG AGCGGATTCA GGAGGAGGCT 450

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500
CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500
CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500
CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500
CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500

rs35979566 (*15, c.1172T>A)

CAGTGTCTGA TAGAGGAGCT TCGGAAATCC AAGGGGGCCC TCATGGACCC 500

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550
CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550
CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550
CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550
CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550

rs35979566 (*15, c.1172T>A)

CACCTTCCTC TTCCAGTCCA TTACCGCCAA CATCATCTGC TCCATCGTCT 550

93

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600
TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600
TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600
TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600
TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600

rs35979566 (*15, c.1172T>A)

TTGGAAAACG ATTCCACTAC CAAGATCAAG AGTTCCTGAA GATGCTGAAC 600

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650
TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650
TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650
TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650
TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650

rs35979566 (*15, c.1172T>A)

TTGTTCTACC AGACTTTTTC ACTCATCAGC TCTGTATTCG GCCAGCTGTT 650

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700
TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700
TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700
TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700
TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700

rs35979566 (*15, c.1172T>A)

TGAGCTCTTC TCTGGCTTCT TGAAATACTT TCCTGGGGCA CACAGGCAAG 700
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750
TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750
TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750
TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750
TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750

rs35979566 (*15, c.1172T>A)

TTTACAAAAA CCTGCAGGAA ATCAATGCTT ACATTGGCCA CAGTGTGGAG 750

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800
AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800
AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAGGGACC TCATCGACAC 800
AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800
AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800

rs35979566 (*15, c.1172T>A)

AAGCACCGTG AAACCCTGGA CCCCAGCGCC CCCAAGGACC TCATCGACAC 800

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850
CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850
CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850
CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850
CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850

rs35979566 (*15, c.1172T>A)

CTACCTGCTC CACATGGAAA AAGAGAAATC CAACGCACAC AGTGAATTCA 850
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900
GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900
GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900
GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900
GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900

rs35979566 (*15, c.1172T>A)

GCCACCAGAA CCTCAACCTC AACACGCTCT CGCTCTTCTT TGCTGGCACT 900

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950
GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950
GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950
GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950
GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950

rs35979566 (*15, c.1172T>A)

GAGACCACCA GCACCACTCT CCGCTACGGC TTCCTGCTCA TGCTCAAATA 950

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000
CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000
CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000
CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000
CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000

rs35979566 (*15, c.1172T>A)

CCCTCATGTT GCAGAGAGAG TCTACAGGGA GATTGAACAG GTGATTGGCC 1000
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050
CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050
CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050
CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050
CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050

rs35979566 (*15, c.1172T>A)

CACATCGCCC TCCAGAGCTT CATGACCGAG CCAAAATGCC ATACACAGAG 1050

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100
GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100
GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100
GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100
GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100

rs35979566 (*15, c.1172T>A)

GCAGTCATCT ATGAGATTCA GAGATTTTCC GACCTTCTCC CCATGGGTGT 1100

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150
GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150
GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150
GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150
GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150

rs35979566 (*15, c.1172T>A)

GCCCCACATT GTCACCCAAC ACACCAGCTT CCGAGGGTAC ATCATCCCCA 1150
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200
AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200
AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200
AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200
AGGACACAGA AGTATTTCTC ATCCTGAGCA CTGCTCTCCA TGACCCACAC 1200

rs35979566 (*15, c.1172T>A)

AGGACACAGA AGTATTTCTC AACCTGAGCA CTGCTCTCCA TGACCCACAC 1200

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250
TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250
TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250
TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250
TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250

rs35979566 (*15, c.1172T>A)

TACTTTGAAA AACCAGACGC CTTCAATCCT GACCACTTTC TGGATGCCAA 1250

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300
TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300
TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300
TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300
TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300

rs35979566 (*15, c.1172T>A)

TGGGGCACTG AAAAAGACTG AAGCTTTTAT CCCCTTCTCC TTAGGGAAGC 1300
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CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350
GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350
GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350
GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350
GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350

rs35979566 (*15, c.1172T>A)

GGATTTGTCT TGGTGAAGGC ATCGCCCGTG CGGAATTGTT CCTCTTCTTC 1350

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400
ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400
ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400
ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400
ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400

rs35979566 (*15, c.1172T>A)

ACCACCATCC TCCAGAACTT CTCCATGGCC AGCCCCGTGG CCCCAGAAGA 1400

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450
CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450
CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450
CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450
CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450

rs35979566 (*15, c.1172T>A)

CATCGATCTG ACACCCCAGG AGTGTGGTGT GGGCAAAATA CCCCCAACAT 1450

99

CYP2B6 Plasmid (NM_000767.4)
Wild Type (CYP2B6*1)
rs2279343 (*4, c.785A>G)
rs3211371 (*5, c.1459C>T)

ACCAGATCCG CTTCCTGCCC CGCTAG 1476
ACCAGATCCG CTTCCTGCCC CGCTAG 1476
ACCAGATCCG CTTCCTGCCC CGCTAG 1476
ACCAGATCTG CTTCCTGCCC CGCTAG 1476

rs8192709 (*2, c.64C>T)
rs12721655 (*8, c.415A>G)

ACCAGATCCG CTTCCTGCCC CGCTAG 1476
ACCAGATCCG CTTCCTGCCC CGCTAG 1476

rs35979566 (*15, c.1172T>A)

ACCAGATCCG CTTCCTGCCC CGCTAG 1476
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APPENDIX C: LIST OF ABBREVIATIONS
AAS… amino acid substitution
ADH… alcohol dehydrogenase
AGP… α1-acid glycoprotein
ANOVA… analysis of variance
CDC… Centers for Disease Control and Prevention
CYP… cytochrome P450
DEA… Drug Enforcement Agency
del… deletion
DNA… deoxyribonucleic acid
EDDP… 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine
EM… extensive metabolizer
EMDP… 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline
FDA… Food and Drug Administration
hERG… human ether-a-go-go related gene
HWE… Hardy-Weinberg equilibrium
IM… intermediate metabolizer
KY… Kentucky
LD… linkage disequilibrium
MAF… minor allele frequency
MMT… methadone maintenance treatment
MOR… µ-opioid receptor
MTD… methadone
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NADPH… nicotinamide adenine dinucleotide phosphate
NCBI… National Center for Biotechnology Information
OCME… Offices of the Chief Medical Examiner
p-HO… para-hydroxy
PolyPhen… polymorphism phenotyping
PM… poor metabolizer
RT-PCR… real-time polymerase chain reaction
SEM… standard error of the mean
SIFT… scale-invariant feature transform
SNP… single nucleotide polymorphism
SRS… substrate recognition site
UM… ultra-rapid metabolizer
UTR… untranslated region
VEP… variant effect predictor
WV… West Virginia
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